US & G7 Countries Make US$ 4.3 Billion In New Commitments To COVAX Global Vaccine Facility – Novavax To Provide 1.1 Billion Vaccine Doses 19/02/2021 Madeleine Hoecklin US President Joe Biden speaking at the Munich Security Conference after the closing of the private G7 meeting on Friday. The United States is donating an additional US$2 billion to the COVAX facility over the next two years to facilitate the equitable distribution of COVID-19 vaccines to low- and middle-income countries, while the pharma company Novavax will provide a total of 1.1 billion doses of its vaccine to COVAX – a gesture that could increase the available vaccine supplies for the global facility by one-third for 2021. The commitment by the US was met by an EU announcement that it would be doubling its COVAX funding, adding an additional €500 million and bringing its total contribution to €1 billion. Germany pledged an additional US$1.8 billion to the Access to COVID-19 Tools (ACT) Accelerator, the majority of which will go towards COVAX, the vaccine platform. Japan committed US$79 million to COVAX as well as Unitaid, and Canada pledged US$59 million. The commitments bring the total funding for the ACT Accelerator to US$10.3 billion, leaving a funding gap of US$22.9 billion for 2021 to fully fund the Accelerator’s work. In addition, the UK and France commited to share some of their surplus doses with low-and middle-income countries after a report that rich countries have stockpiled at least 1 billion vaccine doses more than they need to immunize all of their citizens. Rush of Pledges Coincides With G-7 Meeting The rush of new pledges coincided with Friday’s meeting of the Group of 7 (G-7) most industrialised countries, currently led by the United Kingdom, and including the US, Canada, France, Germany, Italy and Japan. After its meeting on Friday, the G7 leaders released a statement resolving to cooperate to: “accelerate global vaccine development and deployment; work with industry to increase manufacturing capacity, including through voluntary licensing; improve information sharing, such as on sequencing new variants; and, promote transparent and responsible practices, and vaccine confidence.” These commitments come amid criticisms that wealthy nations are hoarding vaccines through bilateral deals and purchasing more doses than is needed to inoculate their populations. In an address to the UN Security Council on Wednesday, UN Secretary-General António Guterres revealed that 10 countries have administered 75% of all COVID-19 vaccines, while over 130 countries have not received a single dose, and less than 1% of doses have been administered in the 32 countries facing severe humanitarian crises. Guterres called the current global vaccine rollout “wildly uneven and unfair” and urged the G7 to create momentum to mobilise the necessary financial resources. Team Europe Pledges European Efforts Will Have Global Impacts “With this new financial boost we want to make sure vaccines are soon delivered to low and middle-income countries,” said Ursula von der Leyen, President of the European Commission, in a press release Friday. “Because we will only be safe if the whole world is safe.” We will only be safe if the whole world is safe As announced in the #G7, the EU is doubling its contribution to #COVAX, the world’s facility for universal access to vaccines – from €500 million to €1 billion. Deliveries will start soon. A true moment of global solidarity. — Ursula von der Leyen (@vonderleyen) February 19, 2021 “Vaccines produced in Europe are now going all over the world and we, as Team Europe, are working to share doses secured under our advanced purchase agreements preferably through COVAX with the Western Balkans, Neighborhood and Africa – benefiting above all health workers and humanitarian needs,” said Stella Kyriakides, Commissioner for Health and Food Safety. The WHO welcomed the new financial commitments from the US, France, Germany, UK and EU to COVAX, which it described as the mechanism “best positioned to deliver vaccines to the world and end the COVID-19 pandemic.” “There is a growing movement behind vaccine equity and I welcome that world leaders are stepping up to the challenge by making new commitments to effectively end this pandemic by sharing doses and increasing funds to COVAX,” said Dr Tedros Adhanom Ghebreyesus, WHO Director General, in a press release. “There is an urgent need for countries to share doses and technology, scale up manufacturing and ensure that there is a sustainable supply of vaccines so that everyone, everywhere can receive a vaccine,” Tedros added. Novavax Commitment to COVAX Meanwhile, Novavax also announced that the company had it signed a Memorandum of Understanding (MoU) with Gavi, The Vaccine Alliance, to provide COVAX with 1.1 billion cumulative doses of its vaccine candidate. The agreement includes the Serum Institute of India, which has a partnership with Novavax to manufacture the vaccine and ensure the broad and equitable distribution of the vaccine in low- and middle-income countries. Gavi had earlier signed an agreement with the Serum Institute to supply COVAX with 100 million doses of the Novavax vaccine, forecasted for delivery in the second quarter of 2021. Gavi and Novavax now currently working to finalise an advance purchase agreement on the new commitment of 1.1 billion doses for COVAX. COVAX’s preliminary forecast of COVID-19 vaccines for 2021 and 2022, as of 20 January – and prior to the recent agreement with Novavax. “We are proud to partner with all the COVAX collaborators and Serum Institute of India to provide global public health leadership and ensure that all countries have broad access to NVX-CoV2373,” said Stanley C. Erck, CEO of Novavax, in a press release. “Novavax will play a critical role in the worldwide effort to provide access to safe and effective vaccines to end the pandemic.” The vaccine candidate is “poised to play a significant role in combating COVID-19 around the world,” said Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI). “This agreement brings the COVAX Facility one step closer to its goal of supplying vaccines globally and ending the acute phase of the pandemic,” said Seth Berkley, CEO of the global vaccine alliance, Gavi, in a press release. “It helps us close in on our goal of delivering two billion doses in 2021 and increases the range of vaccines available to us as we build a portfolio suitable for all settings and contexts.” While the Novavax vaccine has not yet received regulatory or WHO approval, the vaccine demonstrated an efficacy rate of 89.3% two pivotal Phase 3 trials, including a trial in the United Kingdom where the B.117 variant has become dominant, and efficacy of 95.6 % against the original virus strain. A Phase 2b trial in South Africa demonstrated up to 60 percent efficacy against newly emerging escape variants there. The company’s NVX-CoV2373 vaccine is based upon a recombinant nanoparticle technology that generates antigens derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies.i The antigen can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase 1 trials. UK and France Also Make Pledges to Share Extra Doses The UK and France also announced significant new plans to share vaccines to ensure a more equitable distribution of COVID-19 vaccines worldwide. Their pledges came in the wake of a report published on Friday by ONE, an organisation campaigning to end poverty, that rich countries have stockpiled one billion more doses than they need to vaccinate their own populations. According to ONE, Australia, Canada, Japan, the UK, and the US, along with the 27 EU member states could donate one billion doses of vaccines and still have enough doses to inoculate their entire populations. While some countries have expanded on their previous financial commitments to COVAX, the UK announced that it will send the majority of its future surplus vaccines to COVAX and encouraged other member states to follow suit. “As leaders of the G7 we must say today: never again” to the COVID-19 pandemic, said UK Prime Minister Boris Johnson in a statement released on Friday. “By harnessing our collective ingenuity, we can ensure we have the vaccines, treatments and tests to be battle-ready for future health threats, as we beat COVID-19 and build back better together,” he added. In addition to a commitment to share vaccines, Johnson revealed an ambitious plan to reduce the time to develop vaccines for new diseases by two-thirds, aiming to achieve new vaccines in 100 days instead of the unprecedented 300 days it took to develop COVID-19 vaccines. 1/2 PM @BorisJohnson will encourage G7 leaders tomorrow to give more to global vaccinations as he commits the UK to:– Offer surplus vaccines to #COVAX to support developing countries– Work with #G7 partners & @CEPIvaccines to cut vaccine development time by 2/3 to 100 days pic.twitter.com/lucY6v3H9f — G7 Italy (@G7) February 18, 2021 Vaccine-sharing was supported by Emmanuel Macron, France’s President, who urged Europe and the US to allocate up to 5% of their vaccine supplies to low- and middle-income countries, particularly to countries in Africa, in order to play a greater role in the diplomatic vaccine battle. “We are allowing the idea to take hold that hundreds of millions of vaccines are being given in rich countries and that we are not starting in poor countries,” said Macron in an interview with the Financial Times on Thursday. “That idea is unsustainable.” “It’s an unprecedented acceleration of global inequality and it’s politically unsustainable too because it’s paving the way for a war of influence over vaccines,” Macron said. “You can see the Chinese strategy, and the Russian strategy too,” referring to moves from China and Russia to use their vaccines to buy influence in low- and middle-income countries. Emmanuel Macron, President of France, at the Munich Security Conference on Friday. Doses of China’s Sinopharm and Sinovac vaccines have been donated to Zimbabwe, Brunei, Laos, the Philippines, and Cambodia, among others, while Russia has offered the African Union (AU) 300 million doses of the Sputnik V vaccine, along with a financing package for the 55 members of the AU. According to Macron, transferring “3-5 percent of the vaccines we have in stock to Africa” wouldn’t delay domestic inoculation programmes “by a single day.” Macron’s comments were praised by WHO officials on Thursday, with Bruce Aylward, senior advisor to WHO’s Director-General, calling this a “fantastic development.” Aylward appealed to member states to avoid making special vaccine-sharing arrangements outside of COVAX, which is “the best mechanism and the only global mechanism set up” to ensure the equitable allocation of vaccines. “We are encouraging that in the interest of equity and the most equitable distribution possible, those doses go through the COVAX facility, because that way we can coordinate across a massive number of countries and ensure everyone is getting served,” said Aylward at a press briefing on Thursday. US Staged Rollout Of Donations “Today, I’m announcing the United States is making a $2 billion pledge to COVAX with the promise of an additional $2 billion to urge others to step up as well,” said President Biden at the Munich Security Conference on Friday, which was held hours after the G7 meeting ended. The first US$500 million will be made available when the initial COVAX doses begin to be delivered to 92 low- and middle-income countries eligible for donor-supported vaccine distribution through Gavi, The Vaccine Alliance’s Advance Market Commitment (AMC) platform. Another US$1.5 billion will be donated in 2021 and the remaining US$2 billion by the end of 2022. In total, the US will provide COVAX with US$4 billion in funding. The majority of the funds will support direct vaccine procurement, while some funds will be invested in improving country readiness and vaccine service delivery. “The goal is clear: vaccinate vulnerable populations, and reach those without other options,” said a White House statement released ahead of the meeting, which marks new US President Joe Biden’s first major multilateral engagement. Following the announcement, both Seth Berkley and Dr Tedros expressed their thanks to President Biden, with Tedros explaining at the Munich Security Conference that the importance is “not the funding. The US is the major funder of WHO…[but] it’s not the money. It’s the global leadership of the US, its global role is key.” Incredible – this is a vital boost for the @Gavi #COVAX AMC. Thank you President @JoeBiden & @VP @KamalaHarris for your Administration’s commitment to ensuring equitable vaccine access and to playing a key role in the solution to the pandemic: https://t.co/a6tRV1L46D — Seth Berkley (@DrSethBerkley) February 19, 2021 This pledge was also intended to encourage other G7 members to increase their contributions. “We want to turn this into a way to translate $2 billion into several billion dollars, up to at least $15 billion,” a White House official told Reuters. “We also call on our G7 and other partners to work alongside Gavi, to bring in billions more in resources to support global COVID-19 vaccinations, and to target urgent vaccine manufacturing, supply, and delivery needs,” said the statement released on Thursday. “This funding from the Administration will enable Gavi to address urgent needs, while also supporting efforts to diversify and increase contributions from other donors in 2021,” the statement concluded. Image Credits: Munich Security Conference, Gavi. Secrecy Surrounds the Start of Rwanda’s COVID-19 Vaccination Roll-out 19/02/2021 Esther Nakkazi Rwanda started vaccinating health workers against COVID-19 on Monday, but there is confusion about which vaccine it is using or where it has got it from. A local media report said that the Moderna vaccine was being used while the BBC reported that the Pfizer/ BioNtech vaccine was being used. Meanwhile, a source told Health Policy Watch it was the AstraZeneca/ Oxford vaccine. The Rwanda health ministry did not respond to Health Policy Watch queries. The official announcement from the health ministry on Twitter simply said that “international partnerships” had made the vaccination drive possible. According to the Rwandan government, the past week was simply a trial run before a more extensive vaccination rollout in two weeks time with the AstraZeneca/Oxford vaccine from the COVAX facility. Although the source of the initial vaccines has not been confirmed by their government, the World Health Organization (WHO) Africa office said that Rwanda would have acquired these through bilateral arrangements as the COVAX vaccines will only arrive later in the month. Dr. Phionah Atuhebwe, a vaccinologist and the new vaccines introduction medical officer at WHO Africa office, told Health Policy Watch on Tuesday that COVAX had to wait for the WHO decision on an emergency use listing of AstraZeneca before it could dispatch the vaccines. This was granted on Monday. AstraZeneca Due to Arrive Very Soon Atuhebwe said most African countries participating in the COVAX initiative would receive their AstraZeneca doses in the next two weeks. According to the COVAX Interim Distribution Forecast published early February, Rwanda will receive 996,000 AstraZeneca and 102,960 Pfizer/ BioNtech vaccine doses. The WHO Africa office said national regulatory authorities are not compelled to inform WHO of the products they received, but given the unprecedented nature of COVID-19 the office was offering technical support and guidance to ensure the quality, safety and efficacy of products used. In an interview on CNN this week, Rwandan president Paul Kagame said “We will take any vaccines that come that we are told work.” Rwandan President Paul Kagame interviewed on CNN In media reports, Rwanda said it will spend $124million to ensure vaccination coverage of at least 60% of its population. Aside from bilateral agreements and COVAX, African countries will also get vaccines from the African Union platform, the African Vaccine Acquisition Task Team (AVATT). AVATT has secured a provisional 270 million COVID-19 vaccine doses from Pfizer, Johnson & Johnson and AstraZeneca. COVAX also anticipates that, via an existing agreement with AstraZeneca, at least 50 million further doses of the AstraZeneca/Oxford vaccine will be available for delivery to COVAX participants in the first quarter. A few countries in Africa have started COVID-19 limited vaccination drives, mainly for health workers including Mauritius, Guinea, South Africa, Seychelles, Morocco, Algeria and now Rwanda. Pfizer-BioNTech Vaccine Due Soon But Has Stringent Requirements Rwanda is one of only four African countries, together with Cabo Verde, South Africa and Tunisia , to have been approved by COVAX to receive the Pfizer/ BioNTech vaccine, which needs to be stored at minus 70C. According to sources, Pfizer has made access requirements stringent which has made it difficult for some African countries to apply for this vaccine. Aside from the ultra-cold storage, Pfizer has a list of legal requirements including indemnification, liability and compensation for countries that receive its vaccine. Rwanda is scheduled to get 102,960 doses while South Africa will get 117,000, Tunisia 93,600 and Cabo Verde, 5,850, according to the COVAX Interim Distribution Forecast. WHO’s Atuhebwe said this vaccine was expected to arrive within the next week. Meanwhile, Hassan Sibomana, the director of the vaccination unit at Rwanda Biomedical Centre (RBC), said the initial challenge of lack of capacity to store vaccines at minus 70 Celsius (minus 158 Fahrenheit) has been addressed. Five new ultra-cold freezers worth around USD$50,000 have been purchased and the ministry has a capacity to store about 300,000 vaccine doses, Sibomana told the local media, underlining that vaccine safety is their priority to avoid any side effects on people. Rwanda’s new cold storage facility However, Pfizer submitted evidence to the US Food and Drug Authority this week showing that its vaccine could be stored at around minus 25 Celcius to minus 15 C, according to a company media release. “It has been possible to procure some of the Pfizer-BioNTech vaccine for a number of African countries not very extensively, however, it will give us the experience of using this vaccine,” said Matshidiso Moeti, the Regional Director of the WHO Africa Office. Moeti said WHO is working very hard with African countries to finalise their plans for the distribution and delivery of the vaccine and about 34 of the countries on the continent already have their plans ready. A significant roll out of the vaccines in Africa is expected by March this year. “I would like to encourage everyone who has the opportunity when your turn comes in your countries, to be willing to be vaccinated because it’s not only in your own interest in the interest of your immediate family, but also in the interest of the country and in the interest of the continent,” said Moeti. At the WHO Africa press conference last week, Peter Piot, the director of the London School of Hygiene and Tropical Medicine, told reporters that having access to vaccines in Africa, is not only a moral issue but a matter of solidarity. “This is going to become one of the big geopolitical issues of our time – access to vaccination. There, there are contracts through COVAX, the African Union and others. However, manufacturing is lagging behind. And scarcity is a big enemy of equity. So we need to really invest more in manufacturing, including in manufacturing that can happen in Africa.” Over 160,000 Deaths in Five Biggest Cities Linked to Air Pollution in 2020 19/02/2021 Disha Shetty Air pollution has been linked to the deaths of 160,000 people in the world’s five biggest cities in 2020, according a global report by Greenpeace Southeast Asia and IQAir, the world’s largest free air quality information platform. Of the five biggest cities, Delhi had the most deaths (54,000) due to PM2.5 air pollution in 2020 – one death per 500 people. It was followed by Tokyo (40,000) and Shanghai (39,000). Sao Paulo and Mexico City had an estimated 15,000 each. Greenpeace and IQAir collaborated on the ‘cost of air pollution estimator’ for 26 cities, drawing on data from over 80,000 air sensors in IQAir’s air quality database. The Cost Estimator is based on a methodology developed by the Centre for Research on Energy and Clean Air. The IQAir platform measures ground-level particulate matter (PM2.5) in real time and this data is then combined with a city’s population, health data, and scientific risk models to determine mortality and cost estimates. The report estimates that Tokyo (USD$43 billion lost), Los Angeles (USD$43 billion) and New York (USD$25 million) have paid the highest economic cost for air pollution in the past year. “When governments choose coal, oil and gas over clean energy, it’s our health that pays the price. Air pollution from burning fossil fuels increases our likelihood of dying from cancer or stroke, suffering asthma attacks and of experiencing severe COVID-19. We can’t afford to keep breathing dirty air when the solutions to air pollution are widely available and affordable,” said Avinash Chanchal, climate campaigner at Greenpeace India. “Breathing should not be deadly,” said Frank Hammes, CEO of IQAir. “Governments, corporations and individuals must do more to eliminate the sources of air pollution and make our cities better places to live.” Developing Countries Worst Affected Air pollution kills an estimated seven million every year, according to the World Health Organization (WHO). Those in the developing world are disproportionately affected with 9 out of 10 people breathing air whose quality exceeds WHO guideline limits. Air pollution also leads to increased morbidity and healthcare costs due to disability, asthma and chronic respiratory diseases. These translate into lost income for family members and their caregivers, as well as lower economic productivity. This was also reflected in the report which found that two cities in India lost over one-tenth of their GDP due to air pollution in 2020. Lucknow lost 14% of its GDP, followed by Delhi at 13%. The Indo-Gangetic plain in northern India is one of the world’s worst affected regions due to air pollution. Recent evidence has linked air pollution to miscarriages and stillbirths in the region as well. “In most parts of the world it is now cheaper to build clean energy infrastructure than to continue investing in polluting fossil fuels, even before taking the cost of air pollution and climate change into account,” said Bondan Andriyanu, campaigner at Greenpeace Indonesia. “As governments look to recover from the economic impact of COVID, they must create green jobs, build accessible, clean-energy powered public transport systems and invest in renewable energy sources like wind and solar.” Image Credits: Rashed Shumon. WHO Sending Experts & Vaccines to Combat Widening Circle Of Ebola Virus In DR Congo & Guinea – Epicenter Of The 2014-2016 West Africa Epidemic 18/02/2021 Paul Adepoju & Raisa Santos New Ebola vaccines hold promise to curb various virus strains (Credit: WHO) The World Health Organization is set to deploy over 100 experts to Guinea – to respond to a widening circle of Ebola virus cases in a country that was also at the epicenter of the historic 2013-2016 West African Ebola outbreak, officials said at twin press events in Brazzaville and Geneva on Thursday. As critical new vaccines are being rushed to the region, there is a growing concern about transmission abroad, said Health Emergencies Executive Director Mike Ryan at a WHO press conference in Geneva. He noted that Guinea’s initial cluster of cases has occurred in proximity to Nzérékoré, the country’s second-largest city, at the crossroads of routes to Liberia, Côte d’Ivoire, and elsewhere. “Remember that these governments are currently responding to COVID-19 outbreaks in their own countries, while having to either respond to Ebola, or prepare for the potential arrival of Ebola,” said Ryan. WHO African Region Sounding Alarm Speaking at another press briefing in Brazzaville, WHO’s African Regional Director sounded an even greater note of alarm. “It’s a huge concern to see the resurgence of Ebola in Guinea, a country which has already suffered so much from the disease,” said Dr Matshidiso Moeti, WHO Regional Director for Africa at the briefing. However, banking on the expertise and experience built during the previous outbreak, health teams in Guinea are on the move to quickly trace the path of the virus and curb further infections,” she added, saying that “WHO is supporting the authorities to set up testing, contact-tracing and treatment structures and to bring the overall response to full speed.” WHO staff are already on the ground at Guinea, providing surveillance as well as ramping up infection, prevention, and control of health facilities. A humanitarian flight arrived on 15 February in N’Zerekore with 700 kg of medical equipment donated by WHO and partners. The country is also grappling with a surge of COVID-19 cases. On Feb 14 when the new Ebola outbreak in Guinea was announced, the country had also reported 72 new cases of COVID-19. As of Thursdsay, the cumulative number of confirmed COVID-19 cases in Guinea had risen to 15,088 with a total of 85 deaths. Using the glass half full or empty analogy, Moeti noted that Guinean response to COVID-19 and Ebola at the same time could be mutually reinforcing – building on already established guidelines and good practices, particularly around coordination, engaging with communities and leadership. “That also comes from preventive measures like physical distancing for COVID-19 and ‘don’t touch’ messages for Ebola, as well as the importance of hand hygiene for both,” she said. Rapid Ebola Vaccines Rollout – The Keys To Fast Containment House in Equateur Province gets disinfected following discovery of confirmed Ebola case there in August, 2020. Along with the outbreak in Guinea, another new DRC cluster has now emerged in Butembo. But like with COVID-19, vaccination will provide an even more durable response. A consignment of more than 11,000 doses of Ebola vaccine was expected to arrive in Guinea this weekend. In addition, more than 8,500 doses are being shipped from the United States for a total of 20,000 doses. Vaccination is set to kick off soon after they arrive. Some 4,000 kilometers away, another Ebola accination drive was just launched in the city of Butembo, Democratic Republic of Congo, on 15 February – shortly after another Ebola virus outbreak was detected in there on 7 February involving four cases and two deaths so far, according to WHO’s African Regional Office. But unlike Guinea, DR Congo did not have to wait for Ebola vaccines from Geneva or the US as it had 8,000 doses remaining from an Ebola outbreak last year, and thus was immediately able to commence immunizations. “So far nearly 70 people have been vaccinated against Ebola. The quick roll-out of vaccines is a testament to the enormous local capacity built in the previous outbreaks by the government, WHO and partners,” Moeti said. As a new and powerful Ebola control tool in both the Guinea and DR Congo response, WHO is simultaneously trying to step up procurement and rollout of a recently-approved Ebola vaccine through a new global vaccine stockpile. The vaccine was instrumental in finally stamping out a much larger 2018-2019 Ebola outbreak in the eastern part of the Democratic Republic of Congo. The single-dose Ebola vaccine (rVSV∆G-ZEBOV-GP, live), manufactured by Merck, Sharp & Dohme (MSD), received emergency regulatory approval from the US Food and Drug Administration in 2019. In addition, Johnson & Johnson also received European Medicines Agency approval last year for its Ebola vaccine, a two-dose regimen of Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). “The ultimate endpoint for this is a multi-valent vaccine capable of protecting against multiple Ebola strains,” said Ryan at the briefing. The precise Ebola virus strain responsible for the Guinea outbreak has not yet been determined. The WHO, UNICEF, International Federation of Red Cross and Red Crescent Societies (IFRC) and Médecins Sans Frontières (MSF) announced in January the establishment of a global Ebola vaccine stockpile to ensure rapid response to future outbreaks. In his remarks in Geneva, Ryan lauded both Merck and Johnson & Johnson for pushing ahead with the R&D on the vaccines – as well as seeing to their production at cost. “These measures have been implemented to protect vulnerable populations,” said Ryan, adding that people at risk include “not just healthcare workers, but “occupational workers, charcoal workers, and people who work in the rainforest” – groups that might also have contact with animals carrying the Ebola virus. “This is really the holy grail of Ebola is to have those countermeasures in place, and not just be responding to outbreaks, but preventing the recurrence by the pre-emptive practical use of vaccination, which is always the best way to use vaccines.” Rapid Response in Guinea – Result of Hard Experience in 2013-16 West African Outbreak WHO has released some US$ 1.25 million to support the response in Guinea and to shore-up readiness in six neighbouring countries. “Within the epicentre of the outbreak in a border area, the sub-region is on high alert and authorities are reinforcing public health measures, including surveillance, to quickly respond to possible cross-border infections,” Moeti said. In other aspects of the response, Guinea’s Ministry of Health has activated national district and emergency management committees, and have advised the public to take measures to avert the spread of the disease, and to report any persons with symptoms to seek care. The ongoing, rapid response in Guinea and preparedness in neighboring countries is a result of the experience gained during the 2013-2016 outbreak in West Africa. The Ministry of Health of Guinea first reported to WHO about a cluster of Ebola Virus Disease (EVD) cases on 14 February, in the sub-prefecture of Gouécké, Nzérékoré Region, Guinea. Patient Zero was a nurse who originally presented at a health center in the region on 18 January 2021 with symptoms of headache, physical weakness, nausea, vomiting, loss of appetite, abdominal pain, and fever. She was diagnosed with malaria. On 24 January, she consulted with a traditional practitioner in Nzérékoré, and died four days later on 28 January. She was buried unsafely on 1 February in Gouécké, a town in the Nzérékoré Prefecture of Guinea. The other six known cases are her five family members and a traditional practitioner that she first visited for treatment. Of these seven reported cases, five people have already died. The other two confirmed cases are currently in isolation in dedicated health facilities in the Conakry and Gouécké, Nzérékoré region. As of 15 February, some 192 contacts of the nurse had been identified, including in N’Zérékoré Health District and 28 in Ratoma Health District, Conakry. To date, none of these contacts have reported traveling to neighboring countries. The Ebola virus strain responsible for the Guinea outbreak has not yet been determined. Image Credits: Trocaire/Flickr, Twitter: @WHO, WHO. WHO Official Walks Back On China Comments About Imported Frozen Foods As Possible Source Of 2019 Wuhan SARS-CoV2 Outbreak 18/02/2021 Elaine Ruth Fletcher Chinese and WHO-International team present findings Tuesday in Wuhan on joint study of the SARS-CoV2 virus origins in Wuhan briefing, 9 February. Since then, the narratives have diverged significantly. The WHO head of the international expert mission to China to investigate the origins of the SARS-CoV2 virus, told a press briefing Thursday that the international expert group is not seriously considering the Chinese theory that the virus outbreak in Wuhan, first infected Wuhan residents through imported frozen foods. The theory that imported frozen foods first brought the virus to Wuhan from another country -was promoted by the head of the Chinese expert team, Dr Liang Wannian, appearing on the stage with WHO team coordinator, Dr Peter Ben Embarek, at a joint press conference at the close of the joint WHO-China mission on 9 February – and undisputed by the WHO official at the time. That theory has since been discounted by other international experts that participated in the mission as both unlikely – and part of a broader propaganda package that Beijing is trying to sell abroad – to deflect international blame for the pandemic. Speaking about the discrepancies in the Chinese, WHO and international team statements for the first time, Ben Embarek discounted the possibility that the Wuhan virus outbreak had been sparked by contaminated frozen foods imported from abroad – calling such transmission a “very, very rare event” that could only occur after the SARS-CoV-2 virus was really widespread. However, Ben Embarek, a WHO food safety expert, did say that the investigative team is keen to get more data from China about whether wild animals that are farmed domestically in China – and sold on the Wuhan markets in both fresh and frozen forms – could have been the original source of the first animal-to-human virus leap, which then spread more widely among Wuhan residents in late 2019. Paving Over Differences In Chinese and WHO/International Narrative Dr Peter Benembarek, WHO head of the SARS-CoV2 investigative team mission to Wuhan, China In his comments at the Thursday briefing, Ben Embarek tried to paper over the obvious differences in the Chinese and international narratives. “We are talking about two very different situations,” Ben Embarek said at the briefing. “The first one is the possibility of reintroduction of the virus, through the frozen food chain, and through imported products back into China, where the virus has been more or less eliminated,…and where we know that there are multiple outbreaks in food factories in countries where the virus is circulated. “So that’s one line of interest, particularly for China and other countries in a similar situation. It’s a very very rare event, even China, through their extensives search for positive contaminated products have found only a very few positive cases.” The question of the first Wuhan cases in 2019, he added, “is a very different situation at that time, the virus was not widely circulating in the world. There were no large outbreaks in food factories around the world. And therefore, the hypothesis, the idea of importing the virus to China to that food is not something that we’re looking at there.” Ben Embarek also stressed that WHO and International expert team members would still like to get further information about possible infection chains in the domestic wild food products that were arriving in the market. Cautious WHO Statements In Wuhan Contrast With Bolster Media Remarks in Geneva – About Virus Origins and Earlier Spread Ben Embarek’s remarks about the team’s findings since leaving China have signalled a striking change in tone and pitch by the WHO leadership about the investigation. At the Wuhan press conference Embarek also said that the international investigators had not found any concrete evidence that the SARS-CoV-2 virus was circulating in Wuhan prior to December 2019 – another part of the Chinese official narrative. However in an interview Tuesday, Ben Embarek told CNN that the WHO-international team of investigators believed that the December 2019 outbreak in Wuhan, was much wider than previously thought – suggesting it also began earlier as well. . “The virus was circulating widely in Wuhan in December, which is a new finding,” he said. Other international team members have since complained bitterly that politics took precedence over science on key aspects of the mission,- and that Chinese authorities won’t turn over critical patient data that would allow the team to ascertain the breadth of the virus circulation in December 2019, as well as earlier. Ben Embarek has since admitted that the WHO-international team is also still seeking Chinese government permission to access to some 200,000 samples from Wuhan’s blood donor bank, which – if tested for virus antigens – could shed far greater light on the true prevalence of the virus in that period. “There is about 200,000 samples available there that are now secured and could be used for a new set of studies,” Ben Embarek told CNN. “It would be fantastic if we could [work] with that.” Chinese authorities have, however resisted sharing that data, claiming that they are only to be used for litigation purposes. “There is no mechanism to allow for routine studies with that kind of sample.” Over a Dozen SARS-CoV2 Virus Strains In Circulation in Wuhan In December, 2019 During its Wuhan visit, the international team documented that there were already over a dozen strains of the SARS-CoV2 virus circulating in Wuhan in December – some linked to local animal markets and some now. And that is further testimony to its wider spread – Ben Embarek also acknolwedged in the CNN interview. And the team also had a chance to speak to the first patient Chinese officials said had been infected, an office worker in his 40s, with no travel history of note, whose infection was reported on December 8. During the meetings with WHO and international colleagues, Chinese scientists reported that there had been only 174 COVID-19 cases reported throughout Wuhan in December 2019. However, Ben Embarek stressed this was likely to be only the tip of the iceberg – since so many COVID-19 cases are mild or asymptomatic and thus go unreported. “We haven’t done any modeling of that since,” he said. “But we know …in big ballpark figures… out of the infected population, about 15% end up as severe cases, and the vast majority are mild cases.” Official Chinese Statements Peddle Frozen Food Theory The joint WHO-Chinese experts present the frozen food theory for the emergence of SARS-CoV2 in Wuhan a the 9 February press conference wrapping up the WHO -International expert mission. For the past several months, official Chinese statements have sought to shift the narrative around the virus origins elsewhere – suggesting at different times that it emerged from an infection at a military base, or from an animal source in South East Asia. But the favorite theory to be peddled has been that the virus arrived in Wuhan on frozen food packaging from imported products. “All available evidence suggests that (the coronavirus) did not start in central China’s Wuhan, but may come into China through imported frozen food products and their packaging,” stated The People’s Daily in an article in December 2020, At the joint WHO-China press conference earlier this month, Dr Liang Wannian, head of the Chinese expert panel on COVID-19, echoed that narrative once again, asserting that: “studies have shown that the virus can survive for a long time not only at low temperatures, but also at refrigerator temperature, indicating that it can be carried long distances on culturing products.” . Image Credits: @PeterDaszak, WHO. Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Secrecy Surrounds the Start of Rwanda’s COVID-19 Vaccination Roll-out 19/02/2021 Esther Nakkazi Rwanda started vaccinating health workers against COVID-19 on Monday, but there is confusion about which vaccine it is using or where it has got it from. A local media report said that the Moderna vaccine was being used while the BBC reported that the Pfizer/ BioNtech vaccine was being used. Meanwhile, a source told Health Policy Watch it was the AstraZeneca/ Oxford vaccine. The Rwanda health ministry did not respond to Health Policy Watch queries. The official announcement from the health ministry on Twitter simply said that “international partnerships” had made the vaccination drive possible. According to the Rwandan government, the past week was simply a trial run before a more extensive vaccination rollout in two weeks time with the AstraZeneca/Oxford vaccine from the COVAX facility. Although the source of the initial vaccines has not been confirmed by their government, the World Health Organization (WHO) Africa office said that Rwanda would have acquired these through bilateral arrangements as the COVAX vaccines will only arrive later in the month. Dr. Phionah Atuhebwe, a vaccinologist and the new vaccines introduction medical officer at WHO Africa office, told Health Policy Watch on Tuesday that COVAX had to wait for the WHO decision on an emergency use listing of AstraZeneca before it could dispatch the vaccines. This was granted on Monday. AstraZeneca Due to Arrive Very Soon Atuhebwe said most African countries participating in the COVAX initiative would receive their AstraZeneca doses in the next two weeks. According to the COVAX Interim Distribution Forecast published early February, Rwanda will receive 996,000 AstraZeneca and 102,960 Pfizer/ BioNtech vaccine doses. The WHO Africa office said national regulatory authorities are not compelled to inform WHO of the products they received, but given the unprecedented nature of COVID-19 the office was offering technical support and guidance to ensure the quality, safety and efficacy of products used. In an interview on CNN this week, Rwandan president Paul Kagame said “We will take any vaccines that come that we are told work.” Rwandan President Paul Kagame interviewed on CNN In media reports, Rwanda said it will spend $124million to ensure vaccination coverage of at least 60% of its population. Aside from bilateral agreements and COVAX, African countries will also get vaccines from the African Union platform, the African Vaccine Acquisition Task Team (AVATT). AVATT has secured a provisional 270 million COVID-19 vaccine doses from Pfizer, Johnson & Johnson and AstraZeneca. COVAX also anticipates that, via an existing agreement with AstraZeneca, at least 50 million further doses of the AstraZeneca/Oxford vaccine will be available for delivery to COVAX participants in the first quarter. A few countries in Africa have started COVID-19 limited vaccination drives, mainly for health workers including Mauritius, Guinea, South Africa, Seychelles, Morocco, Algeria and now Rwanda. Pfizer-BioNTech Vaccine Due Soon But Has Stringent Requirements Rwanda is one of only four African countries, together with Cabo Verde, South Africa and Tunisia , to have been approved by COVAX to receive the Pfizer/ BioNTech vaccine, which needs to be stored at minus 70C. According to sources, Pfizer has made access requirements stringent which has made it difficult for some African countries to apply for this vaccine. Aside from the ultra-cold storage, Pfizer has a list of legal requirements including indemnification, liability and compensation for countries that receive its vaccine. Rwanda is scheduled to get 102,960 doses while South Africa will get 117,000, Tunisia 93,600 and Cabo Verde, 5,850, according to the COVAX Interim Distribution Forecast. WHO’s Atuhebwe said this vaccine was expected to arrive within the next week. Meanwhile, Hassan Sibomana, the director of the vaccination unit at Rwanda Biomedical Centre (RBC), said the initial challenge of lack of capacity to store vaccines at minus 70 Celsius (minus 158 Fahrenheit) has been addressed. Five new ultra-cold freezers worth around USD$50,000 have been purchased and the ministry has a capacity to store about 300,000 vaccine doses, Sibomana told the local media, underlining that vaccine safety is their priority to avoid any side effects on people. Rwanda’s new cold storage facility However, Pfizer submitted evidence to the US Food and Drug Authority this week showing that its vaccine could be stored at around minus 25 Celcius to minus 15 C, according to a company media release. “It has been possible to procure some of the Pfizer-BioNTech vaccine for a number of African countries not very extensively, however, it will give us the experience of using this vaccine,” said Matshidiso Moeti, the Regional Director of the WHO Africa Office. Moeti said WHO is working very hard with African countries to finalise their plans for the distribution and delivery of the vaccine and about 34 of the countries on the continent already have their plans ready. A significant roll out of the vaccines in Africa is expected by March this year. “I would like to encourage everyone who has the opportunity when your turn comes in your countries, to be willing to be vaccinated because it’s not only in your own interest in the interest of your immediate family, but also in the interest of the country and in the interest of the continent,” said Moeti. At the WHO Africa press conference last week, Peter Piot, the director of the London School of Hygiene and Tropical Medicine, told reporters that having access to vaccines in Africa, is not only a moral issue but a matter of solidarity. “This is going to become one of the big geopolitical issues of our time – access to vaccination. There, there are contracts through COVAX, the African Union and others. However, manufacturing is lagging behind. And scarcity is a big enemy of equity. So we need to really invest more in manufacturing, including in manufacturing that can happen in Africa.” Over 160,000 Deaths in Five Biggest Cities Linked to Air Pollution in 2020 19/02/2021 Disha Shetty Air pollution has been linked to the deaths of 160,000 people in the world’s five biggest cities in 2020, according a global report by Greenpeace Southeast Asia and IQAir, the world’s largest free air quality information platform. Of the five biggest cities, Delhi had the most deaths (54,000) due to PM2.5 air pollution in 2020 – one death per 500 people. It was followed by Tokyo (40,000) and Shanghai (39,000). Sao Paulo and Mexico City had an estimated 15,000 each. Greenpeace and IQAir collaborated on the ‘cost of air pollution estimator’ for 26 cities, drawing on data from over 80,000 air sensors in IQAir’s air quality database. The Cost Estimator is based on a methodology developed by the Centre for Research on Energy and Clean Air. The IQAir platform measures ground-level particulate matter (PM2.5) in real time and this data is then combined with a city’s population, health data, and scientific risk models to determine mortality and cost estimates. The report estimates that Tokyo (USD$43 billion lost), Los Angeles (USD$43 billion) and New York (USD$25 million) have paid the highest economic cost for air pollution in the past year. “When governments choose coal, oil and gas over clean energy, it’s our health that pays the price. Air pollution from burning fossil fuels increases our likelihood of dying from cancer or stroke, suffering asthma attacks and of experiencing severe COVID-19. We can’t afford to keep breathing dirty air when the solutions to air pollution are widely available and affordable,” said Avinash Chanchal, climate campaigner at Greenpeace India. “Breathing should not be deadly,” said Frank Hammes, CEO of IQAir. “Governments, corporations and individuals must do more to eliminate the sources of air pollution and make our cities better places to live.” Developing Countries Worst Affected Air pollution kills an estimated seven million every year, according to the World Health Organization (WHO). Those in the developing world are disproportionately affected with 9 out of 10 people breathing air whose quality exceeds WHO guideline limits. Air pollution also leads to increased morbidity and healthcare costs due to disability, asthma and chronic respiratory diseases. These translate into lost income for family members and their caregivers, as well as lower economic productivity. This was also reflected in the report which found that two cities in India lost over one-tenth of their GDP due to air pollution in 2020. Lucknow lost 14% of its GDP, followed by Delhi at 13%. The Indo-Gangetic plain in northern India is one of the world’s worst affected regions due to air pollution. Recent evidence has linked air pollution to miscarriages and stillbirths in the region as well. “In most parts of the world it is now cheaper to build clean energy infrastructure than to continue investing in polluting fossil fuels, even before taking the cost of air pollution and climate change into account,” said Bondan Andriyanu, campaigner at Greenpeace Indonesia. “As governments look to recover from the economic impact of COVID, they must create green jobs, build accessible, clean-energy powered public transport systems and invest in renewable energy sources like wind and solar.” Image Credits: Rashed Shumon. WHO Sending Experts & Vaccines to Combat Widening Circle Of Ebola Virus In DR Congo & Guinea – Epicenter Of The 2014-2016 West Africa Epidemic 18/02/2021 Paul Adepoju & Raisa Santos New Ebola vaccines hold promise to curb various virus strains (Credit: WHO) The World Health Organization is set to deploy over 100 experts to Guinea – to respond to a widening circle of Ebola virus cases in a country that was also at the epicenter of the historic 2013-2016 West African Ebola outbreak, officials said at twin press events in Brazzaville and Geneva on Thursday. As critical new vaccines are being rushed to the region, there is a growing concern about transmission abroad, said Health Emergencies Executive Director Mike Ryan at a WHO press conference in Geneva. He noted that Guinea’s initial cluster of cases has occurred in proximity to Nzérékoré, the country’s second-largest city, at the crossroads of routes to Liberia, Côte d’Ivoire, and elsewhere. “Remember that these governments are currently responding to COVID-19 outbreaks in their own countries, while having to either respond to Ebola, or prepare for the potential arrival of Ebola,” said Ryan. WHO African Region Sounding Alarm Speaking at another press briefing in Brazzaville, WHO’s African Regional Director sounded an even greater note of alarm. “It’s a huge concern to see the resurgence of Ebola in Guinea, a country which has already suffered so much from the disease,” said Dr Matshidiso Moeti, WHO Regional Director for Africa at the briefing. However, banking on the expertise and experience built during the previous outbreak, health teams in Guinea are on the move to quickly trace the path of the virus and curb further infections,” she added, saying that “WHO is supporting the authorities to set up testing, contact-tracing and treatment structures and to bring the overall response to full speed.” WHO staff are already on the ground at Guinea, providing surveillance as well as ramping up infection, prevention, and control of health facilities. A humanitarian flight arrived on 15 February in N’Zerekore with 700 kg of medical equipment donated by WHO and partners. The country is also grappling with a surge of COVID-19 cases. On Feb 14 when the new Ebola outbreak in Guinea was announced, the country had also reported 72 new cases of COVID-19. As of Thursdsay, the cumulative number of confirmed COVID-19 cases in Guinea had risen to 15,088 with a total of 85 deaths. Using the glass half full or empty analogy, Moeti noted that Guinean response to COVID-19 and Ebola at the same time could be mutually reinforcing – building on already established guidelines and good practices, particularly around coordination, engaging with communities and leadership. “That also comes from preventive measures like physical distancing for COVID-19 and ‘don’t touch’ messages for Ebola, as well as the importance of hand hygiene for both,” she said. Rapid Ebola Vaccines Rollout – The Keys To Fast Containment House in Equateur Province gets disinfected following discovery of confirmed Ebola case there in August, 2020. Along with the outbreak in Guinea, another new DRC cluster has now emerged in Butembo. But like with COVID-19, vaccination will provide an even more durable response. A consignment of more than 11,000 doses of Ebola vaccine was expected to arrive in Guinea this weekend. In addition, more than 8,500 doses are being shipped from the United States for a total of 20,000 doses. Vaccination is set to kick off soon after they arrive. Some 4,000 kilometers away, another Ebola accination drive was just launched in the city of Butembo, Democratic Republic of Congo, on 15 February – shortly after another Ebola virus outbreak was detected in there on 7 February involving four cases and two deaths so far, according to WHO’s African Regional Office. But unlike Guinea, DR Congo did not have to wait for Ebola vaccines from Geneva or the US as it had 8,000 doses remaining from an Ebola outbreak last year, and thus was immediately able to commence immunizations. “So far nearly 70 people have been vaccinated against Ebola. The quick roll-out of vaccines is a testament to the enormous local capacity built in the previous outbreaks by the government, WHO and partners,” Moeti said. As a new and powerful Ebola control tool in both the Guinea and DR Congo response, WHO is simultaneously trying to step up procurement and rollout of a recently-approved Ebola vaccine through a new global vaccine stockpile. The vaccine was instrumental in finally stamping out a much larger 2018-2019 Ebola outbreak in the eastern part of the Democratic Republic of Congo. The single-dose Ebola vaccine (rVSV∆G-ZEBOV-GP, live), manufactured by Merck, Sharp & Dohme (MSD), received emergency regulatory approval from the US Food and Drug Administration in 2019. In addition, Johnson & Johnson also received European Medicines Agency approval last year for its Ebola vaccine, a two-dose regimen of Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). “The ultimate endpoint for this is a multi-valent vaccine capable of protecting against multiple Ebola strains,” said Ryan at the briefing. The precise Ebola virus strain responsible for the Guinea outbreak has not yet been determined. The WHO, UNICEF, International Federation of Red Cross and Red Crescent Societies (IFRC) and Médecins Sans Frontières (MSF) announced in January the establishment of a global Ebola vaccine stockpile to ensure rapid response to future outbreaks. In his remarks in Geneva, Ryan lauded both Merck and Johnson & Johnson for pushing ahead with the R&D on the vaccines – as well as seeing to their production at cost. “These measures have been implemented to protect vulnerable populations,” said Ryan, adding that people at risk include “not just healthcare workers, but “occupational workers, charcoal workers, and people who work in the rainforest” – groups that might also have contact with animals carrying the Ebola virus. “This is really the holy grail of Ebola is to have those countermeasures in place, and not just be responding to outbreaks, but preventing the recurrence by the pre-emptive practical use of vaccination, which is always the best way to use vaccines.” Rapid Response in Guinea – Result of Hard Experience in 2013-16 West African Outbreak WHO has released some US$ 1.25 million to support the response in Guinea and to shore-up readiness in six neighbouring countries. “Within the epicentre of the outbreak in a border area, the sub-region is on high alert and authorities are reinforcing public health measures, including surveillance, to quickly respond to possible cross-border infections,” Moeti said. In other aspects of the response, Guinea’s Ministry of Health has activated national district and emergency management committees, and have advised the public to take measures to avert the spread of the disease, and to report any persons with symptoms to seek care. The ongoing, rapid response in Guinea and preparedness in neighboring countries is a result of the experience gained during the 2013-2016 outbreak in West Africa. The Ministry of Health of Guinea first reported to WHO about a cluster of Ebola Virus Disease (EVD) cases on 14 February, in the sub-prefecture of Gouécké, Nzérékoré Region, Guinea. Patient Zero was a nurse who originally presented at a health center in the region on 18 January 2021 with symptoms of headache, physical weakness, nausea, vomiting, loss of appetite, abdominal pain, and fever. She was diagnosed with malaria. On 24 January, she consulted with a traditional practitioner in Nzérékoré, and died four days later on 28 January. She was buried unsafely on 1 February in Gouécké, a town in the Nzérékoré Prefecture of Guinea. The other six known cases are her five family members and a traditional practitioner that she first visited for treatment. Of these seven reported cases, five people have already died. The other two confirmed cases are currently in isolation in dedicated health facilities in the Conakry and Gouécké, Nzérékoré region. As of 15 February, some 192 contacts of the nurse had been identified, including in N’Zérékoré Health District and 28 in Ratoma Health District, Conakry. To date, none of these contacts have reported traveling to neighboring countries. The Ebola virus strain responsible for the Guinea outbreak has not yet been determined. Image Credits: Trocaire/Flickr, Twitter: @WHO, WHO. WHO Official Walks Back On China Comments About Imported Frozen Foods As Possible Source Of 2019 Wuhan SARS-CoV2 Outbreak 18/02/2021 Elaine Ruth Fletcher Chinese and WHO-International team present findings Tuesday in Wuhan on joint study of the SARS-CoV2 virus origins in Wuhan briefing, 9 February. Since then, the narratives have diverged significantly. The WHO head of the international expert mission to China to investigate the origins of the SARS-CoV2 virus, told a press briefing Thursday that the international expert group is not seriously considering the Chinese theory that the virus outbreak in Wuhan, first infected Wuhan residents through imported frozen foods. The theory that imported frozen foods first brought the virus to Wuhan from another country -was promoted by the head of the Chinese expert team, Dr Liang Wannian, appearing on the stage with WHO team coordinator, Dr Peter Ben Embarek, at a joint press conference at the close of the joint WHO-China mission on 9 February – and undisputed by the WHO official at the time. That theory has since been discounted by other international experts that participated in the mission as both unlikely – and part of a broader propaganda package that Beijing is trying to sell abroad – to deflect international blame for the pandemic. Speaking about the discrepancies in the Chinese, WHO and international team statements for the first time, Ben Embarek discounted the possibility that the Wuhan virus outbreak had been sparked by contaminated frozen foods imported from abroad – calling such transmission a “very, very rare event” that could only occur after the SARS-CoV-2 virus was really widespread. However, Ben Embarek, a WHO food safety expert, did say that the investigative team is keen to get more data from China about whether wild animals that are farmed domestically in China – and sold on the Wuhan markets in both fresh and frozen forms – could have been the original source of the first animal-to-human virus leap, which then spread more widely among Wuhan residents in late 2019. Paving Over Differences In Chinese and WHO/International Narrative Dr Peter Benembarek, WHO head of the SARS-CoV2 investigative team mission to Wuhan, China In his comments at the Thursday briefing, Ben Embarek tried to paper over the obvious differences in the Chinese and international narratives. “We are talking about two very different situations,” Ben Embarek said at the briefing. “The first one is the possibility of reintroduction of the virus, through the frozen food chain, and through imported products back into China, where the virus has been more or less eliminated,…and where we know that there are multiple outbreaks in food factories in countries where the virus is circulated. “So that’s one line of interest, particularly for China and other countries in a similar situation. It’s a very very rare event, even China, through their extensives search for positive contaminated products have found only a very few positive cases.” The question of the first Wuhan cases in 2019, he added, “is a very different situation at that time, the virus was not widely circulating in the world. There were no large outbreaks in food factories around the world. And therefore, the hypothesis, the idea of importing the virus to China to that food is not something that we’re looking at there.” Ben Embarek also stressed that WHO and International expert team members would still like to get further information about possible infection chains in the domestic wild food products that were arriving in the market. Cautious WHO Statements In Wuhan Contrast With Bolster Media Remarks in Geneva – About Virus Origins and Earlier Spread Ben Embarek’s remarks about the team’s findings since leaving China have signalled a striking change in tone and pitch by the WHO leadership about the investigation. At the Wuhan press conference Embarek also said that the international investigators had not found any concrete evidence that the SARS-CoV-2 virus was circulating in Wuhan prior to December 2019 – another part of the Chinese official narrative. However in an interview Tuesday, Ben Embarek told CNN that the WHO-international team of investigators believed that the December 2019 outbreak in Wuhan, was much wider than previously thought – suggesting it also began earlier as well. . “The virus was circulating widely in Wuhan in December, which is a new finding,” he said. Other international team members have since complained bitterly that politics took precedence over science on key aspects of the mission,- and that Chinese authorities won’t turn over critical patient data that would allow the team to ascertain the breadth of the virus circulation in December 2019, as well as earlier. Ben Embarek has since admitted that the WHO-international team is also still seeking Chinese government permission to access to some 200,000 samples from Wuhan’s blood donor bank, which – if tested for virus antigens – could shed far greater light on the true prevalence of the virus in that period. “There is about 200,000 samples available there that are now secured and could be used for a new set of studies,” Ben Embarek told CNN. “It would be fantastic if we could [work] with that.” Chinese authorities have, however resisted sharing that data, claiming that they are only to be used for litigation purposes. “There is no mechanism to allow for routine studies with that kind of sample.” Over a Dozen SARS-CoV2 Virus Strains In Circulation in Wuhan In December, 2019 During its Wuhan visit, the international team documented that there were already over a dozen strains of the SARS-CoV2 virus circulating in Wuhan in December – some linked to local animal markets and some now. And that is further testimony to its wider spread – Ben Embarek also acknolwedged in the CNN interview. And the team also had a chance to speak to the first patient Chinese officials said had been infected, an office worker in his 40s, with no travel history of note, whose infection was reported on December 8. During the meetings with WHO and international colleagues, Chinese scientists reported that there had been only 174 COVID-19 cases reported throughout Wuhan in December 2019. However, Ben Embarek stressed this was likely to be only the tip of the iceberg – since so many COVID-19 cases are mild or asymptomatic and thus go unreported. “We haven’t done any modeling of that since,” he said. “But we know …in big ballpark figures… out of the infected population, about 15% end up as severe cases, and the vast majority are mild cases.” Official Chinese Statements Peddle Frozen Food Theory The joint WHO-Chinese experts present the frozen food theory for the emergence of SARS-CoV2 in Wuhan a the 9 February press conference wrapping up the WHO -International expert mission. For the past several months, official Chinese statements have sought to shift the narrative around the virus origins elsewhere – suggesting at different times that it emerged from an infection at a military base, or from an animal source in South East Asia. But the favorite theory to be peddled has been that the virus arrived in Wuhan on frozen food packaging from imported products. “All available evidence suggests that (the coronavirus) did not start in central China’s Wuhan, but may come into China through imported frozen food products and their packaging,” stated The People’s Daily in an article in December 2020, At the joint WHO-China press conference earlier this month, Dr Liang Wannian, head of the Chinese expert panel on COVID-19, echoed that narrative once again, asserting that: “studies have shown that the virus can survive for a long time not only at low temperatures, but also at refrigerator temperature, indicating that it can be carried long distances on culturing products.” . Image Credits: @PeterDaszak, WHO. Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Over 160,000 Deaths in Five Biggest Cities Linked to Air Pollution in 2020 19/02/2021 Disha Shetty Air pollution has been linked to the deaths of 160,000 people in the world’s five biggest cities in 2020, according a global report by Greenpeace Southeast Asia and IQAir, the world’s largest free air quality information platform. Of the five biggest cities, Delhi had the most deaths (54,000) due to PM2.5 air pollution in 2020 – one death per 500 people. It was followed by Tokyo (40,000) and Shanghai (39,000). Sao Paulo and Mexico City had an estimated 15,000 each. Greenpeace and IQAir collaborated on the ‘cost of air pollution estimator’ for 26 cities, drawing on data from over 80,000 air sensors in IQAir’s air quality database. The Cost Estimator is based on a methodology developed by the Centre for Research on Energy and Clean Air. The IQAir platform measures ground-level particulate matter (PM2.5) in real time and this data is then combined with a city’s population, health data, and scientific risk models to determine mortality and cost estimates. The report estimates that Tokyo (USD$43 billion lost), Los Angeles (USD$43 billion) and New York (USD$25 million) have paid the highest economic cost for air pollution in the past year. “When governments choose coal, oil and gas over clean energy, it’s our health that pays the price. Air pollution from burning fossil fuels increases our likelihood of dying from cancer or stroke, suffering asthma attacks and of experiencing severe COVID-19. We can’t afford to keep breathing dirty air when the solutions to air pollution are widely available and affordable,” said Avinash Chanchal, climate campaigner at Greenpeace India. “Breathing should not be deadly,” said Frank Hammes, CEO of IQAir. “Governments, corporations and individuals must do more to eliminate the sources of air pollution and make our cities better places to live.” Developing Countries Worst Affected Air pollution kills an estimated seven million every year, according to the World Health Organization (WHO). Those in the developing world are disproportionately affected with 9 out of 10 people breathing air whose quality exceeds WHO guideline limits. Air pollution also leads to increased morbidity and healthcare costs due to disability, asthma and chronic respiratory diseases. These translate into lost income for family members and their caregivers, as well as lower economic productivity. This was also reflected in the report which found that two cities in India lost over one-tenth of their GDP due to air pollution in 2020. Lucknow lost 14% of its GDP, followed by Delhi at 13%. The Indo-Gangetic plain in northern India is one of the world’s worst affected regions due to air pollution. Recent evidence has linked air pollution to miscarriages and stillbirths in the region as well. “In most parts of the world it is now cheaper to build clean energy infrastructure than to continue investing in polluting fossil fuels, even before taking the cost of air pollution and climate change into account,” said Bondan Andriyanu, campaigner at Greenpeace Indonesia. “As governments look to recover from the economic impact of COVID, they must create green jobs, build accessible, clean-energy powered public transport systems and invest in renewable energy sources like wind and solar.” Image Credits: Rashed Shumon. WHO Sending Experts & Vaccines to Combat Widening Circle Of Ebola Virus In DR Congo & Guinea – Epicenter Of The 2014-2016 West Africa Epidemic 18/02/2021 Paul Adepoju & Raisa Santos New Ebola vaccines hold promise to curb various virus strains (Credit: WHO) The World Health Organization is set to deploy over 100 experts to Guinea – to respond to a widening circle of Ebola virus cases in a country that was also at the epicenter of the historic 2013-2016 West African Ebola outbreak, officials said at twin press events in Brazzaville and Geneva on Thursday. As critical new vaccines are being rushed to the region, there is a growing concern about transmission abroad, said Health Emergencies Executive Director Mike Ryan at a WHO press conference in Geneva. He noted that Guinea’s initial cluster of cases has occurred in proximity to Nzérékoré, the country’s second-largest city, at the crossroads of routes to Liberia, Côte d’Ivoire, and elsewhere. “Remember that these governments are currently responding to COVID-19 outbreaks in their own countries, while having to either respond to Ebola, or prepare for the potential arrival of Ebola,” said Ryan. WHO African Region Sounding Alarm Speaking at another press briefing in Brazzaville, WHO’s African Regional Director sounded an even greater note of alarm. “It’s a huge concern to see the resurgence of Ebola in Guinea, a country which has already suffered so much from the disease,” said Dr Matshidiso Moeti, WHO Regional Director for Africa at the briefing. However, banking on the expertise and experience built during the previous outbreak, health teams in Guinea are on the move to quickly trace the path of the virus and curb further infections,” she added, saying that “WHO is supporting the authorities to set up testing, contact-tracing and treatment structures and to bring the overall response to full speed.” WHO staff are already on the ground at Guinea, providing surveillance as well as ramping up infection, prevention, and control of health facilities. A humanitarian flight arrived on 15 February in N’Zerekore with 700 kg of medical equipment donated by WHO and partners. The country is also grappling with a surge of COVID-19 cases. On Feb 14 when the new Ebola outbreak in Guinea was announced, the country had also reported 72 new cases of COVID-19. As of Thursdsay, the cumulative number of confirmed COVID-19 cases in Guinea had risen to 15,088 with a total of 85 deaths. Using the glass half full or empty analogy, Moeti noted that Guinean response to COVID-19 and Ebola at the same time could be mutually reinforcing – building on already established guidelines and good practices, particularly around coordination, engaging with communities and leadership. “That also comes from preventive measures like physical distancing for COVID-19 and ‘don’t touch’ messages for Ebola, as well as the importance of hand hygiene for both,” she said. Rapid Ebola Vaccines Rollout – The Keys To Fast Containment House in Equateur Province gets disinfected following discovery of confirmed Ebola case there in August, 2020. Along with the outbreak in Guinea, another new DRC cluster has now emerged in Butembo. But like with COVID-19, vaccination will provide an even more durable response. A consignment of more than 11,000 doses of Ebola vaccine was expected to arrive in Guinea this weekend. In addition, more than 8,500 doses are being shipped from the United States for a total of 20,000 doses. Vaccination is set to kick off soon after they arrive. Some 4,000 kilometers away, another Ebola accination drive was just launched in the city of Butembo, Democratic Republic of Congo, on 15 February – shortly after another Ebola virus outbreak was detected in there on 7 February involving four cases and two deaths so far, according to WHO’s African Regional Office. But unlike Guinea, DR Congo did not have to wait for Ebola vaccines from Geneva or the US as it had 8,000 doses remaining from an Ebola outbreak last year, and thus was immediately able to commence immunizations. “So far nearly 70 people have been vaccinated against Ebola. The quick roll-out of vaccines is a testament to the enormous local capacity built in the previous outbreaks by the government, WHO and partners,” Moeti said. As a new and powerful Ebola control tool in both the Guinea and DR Congo response, WHO is simultaneously trying to step up procurement and rollout of a recently-approved Ebola vaccine through a new global vaccine stockpile. The vaccine was instrumental in finally stamping out a much larger 2018-2019 Ebola outbreak in the eastern part of the Democratic Republic of Congo. The single-dose Ebola vaccine (rVSV∆G-ZEBOV-GP, live), manufactured by Merck, Sharp & Dohme (MSD), received emergency regulatory approval from the US Food and Drug Administration in 2019. In addition, Johnson & Johnson also received European Medicines Agency approval last year for its Ebola vaccine, a two-dose regimen of Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). “The ultimate endpoint for this is a multi-valent vaccine capable of protecting against multiple Ebola strains,” said Ryan at the briefing. The precise Ebola virus strain responsible for the Guinea outbreak has not yet been determined. The WHO, UNICEF, International Federation of Red Cross and Red Crescent Societies (IFRC) and Médecins Sans Frontières (MSF) announced in January the establishment of a global Ebola vaccine stockpile to ensure rapid response to future outbreaks. In his remarks in Geneva, Ryan lauded both Merck and Johnson & Johnson for pushing ahead with the R&D on the vaccines – as well as seeing to their production at cost. “These measures have been implemented to protect vulnerable populations,” said Ryan, adding that people at risk include “not just healthcare workers, but “occupational workers, charcoal workers, and people who work in the rainforest” – groups that might also have contact with animals carrying the Ebola virus. “This is really the holy grail of Ebola is to have those countermeasures in place, and not just be responding to outbreaks, but preventing the recurrence by the pre-emptive practical use of vaccination, which is always the best way to use vaccines.” Rapid Response in Guinea – Result of Hard Experience in 2013-16 West African Outbreak WHO has released some US$ 1.25 million to support the response in Guinea and to shore-up readiness in six neighbouring countries. “Within the epicentre of the outbreak in a border area, the sub-region is on high alert and authorities are reinforcing public health measures, including surveillance, to quickly respond to possible cross-border infections,” Moeti said. In other aspects of the response, Guinea’s Ministry of Health has activated national district and emergency management committees, and have advised the public to take measures to avert the spread of the disease, and to report any persons with symptoms to seek care. The ongoing, rapid response in Guinea and preparedness in neighboring countries is a result of the experience gained during the 2013-2016 outbreak in West Africa. The Ministry of Health of Guinea first reported to WHO about a cluster of Ebola Virus Disease (EVD) cases on 14 February, in the sub-prefecture of Gouécké, Nzérékoré Region, Guinea. Patient Zero was a nurse who originally presented at a health center in the region on 18 January 2021 with symptoms of headache, physical weakness, nausea, vomiting, loss of appetite, abdominal pain, and fever. She was diagnosed with malaria. On 24 January, she consulted with a traditional practitioner in Nzérékoré, and died four days later on 28 January. She was buried unsafely on 1 February in Gouécké, a town in the Nzérékoré Prefecture of Guinea. The other six known cases are her five family members and a traditional practitioner that she first visited for treatment. Of these seven reported cases, five people have already died. The other two confirmed cases are currently in isolation in dedicated health facilities in the Conakry and Gouécké, Nzérékoré region. As of 15 February, some 192 contacts of the nurse had been identified, including in N’Zérékoré Health District and 28 in Ratoma Health District, Conakry. To date, none of these contacts have reported traveling to neighboring countries. The Ebola virus strain responsible for the Guinea outbreak has not yet been determined. Image Credits: Trocaire/Flickr, Twitter: @WHO, WHO. WHO Official Walks Back On China Comments About Imported Frozen Foods As Possible Source Of 2019 Wuhan SARS-CoV2 Outbreak 18/02/2021 Elaine Ruth Fletcher Chinese and WHO-International team present findings Tuesday in Wuhan on joint study of the SARS-CoV2 virus origins in Wuhan briefing, 9 February. Since then, the narratives have diverged significantly. The WHO head of the international expert mission to China to investigate the origins of the SARS-CoV2 virus, told a press briefing Thursday that the international expert group is not seriously considering the Chinese theory that the virus outbreak in Wuhan, first infected Wuhan residents through imported frozen foods. The theory that imported frozen foods first brought the virus to Wuhan from another country -was promoted by the head of the Chinese expert team, Dr Liang Wannian, appearing on the stage with WHO team coordinator, Dr Peter Ben Embarek, at a joint press conference at the close of the joint WHO-China mission on 9 February – and undisputed by the WHO official at the time. That theory has since been discounted by other international experts that participated in the mission as both unlikely – and part of a broader propaganda package that Beijing is trying to sell abroad – to deflect international blame for the pandemic. Speaking about the discrepancies in the Chinese, WHO and international team statements for the first time, Ben Embarek discounted the possibility that the Wuhan virus outbreak had been sparked by contaminated frozen foods imported from abroad – calling such transmission a “very, very rare event” that could only occur after the SARS-CoV-2 virus was really widespread. However, Ben Embarek, a WHO food safety expert, did say that the investigative team is keen to get more data from China about whether wild animals that are farmed domestically in China – and sold on the Wuhan markets in both fresh and frozen forms – could have been the original source of the first animal-to-human virus leap, which then spread more widely among Wuhan residents in late 2019. Paving Over Differences In Chinese and WHO/International Narrative Dr Peter Benembarek, WHO head of the SARS-CoV2 investigative team mission to Wuhan, China In his comments at the Thursday briefing, Ben Embarek tried to paper over the obvious differences in the Chinese and international narratives. “We are talking about two very different situations,” Ben Embarek said at the briefing. “The first one is the possibility of reintroduction of the virus, through the frozen food chain, and through imported products back into China, where the virus has been more or less eliminated,…and where we know that there are multiple outbreaks in food factories in countries where the virus is circulated. “So that’s one line of interest, particularly for China and other countries in a similar situation. It’s a very very rare event, even China, through their extensives search for positive contaminated products have found only a very few positive cases.” The question of the first Wuhan cases in 2019, he added, “is a very different situation at that time, the virus was not widely circulating in the world. There were no large outbreaks in food factories around the world. And therefore, the hypothesis, the idea of importing the virus to China to that food is not something that we’re looking at there.” Ben Embarek also stressed that WHO and International expert team members would still like to get further information about possible infection chains in the domestic wild food products that were arriving in the market. Cautious WHO Statements In Wuhan Contrast With Bolster Media Remarks in Geneva – About Virus Origins and Earlier Spread Ben Embarek’s remarks about the team’s findings since leaving China have signalled a striking change in tone and pitch by the WHO leadership about the investigation. At the Wuhan press conference Embarek also said that the international investigators had not found any concrete evidence that the SARS-CoV-2 virus was circulating in Wuhan prior to December 2019 – another part of the Chinese official narrative. However in an interview Tuesday, Ben Embarek told CNN that the WHO-international team of investigators believed that the December 2019 outbreak in Wuhan, was much wider than previously thought – suggesting it also began earlier as well. . “The virus was circulating widely in Wuhan in December, which is a new finding,” he said. Other international team members have since complained bitterly that politics took precedence over science on key aspects of the mission,- and that Chinese authorities won’t turn over critical patient data that would allow the team to ascertain the breadth of the virus circulation in December 2019, as well as earlier. Ben Embarek has since admitted that the WHO-international team is also still seeking Chinese government permission to access to some 200,000 samples from Wuhan’s blood donor bank, which – if tested for virus antigens – could shed far greater light on the true prevalence of the virus in that period. “There is about 200,000 samples available there that are now secured and could be used for a new set of studies,” Ben Embarek told CNN. “It would be fantastic if we could [work] with that.” Chinese authorities have, however resisted sharing that data, claiming that they are only to be used for litigation purposes. “There is no mechanism to allow for routine studies with that kind of sample.” Over a Dozen SARS-CoV2 Virus Strains In Circulation in Wuhan In December, 2019 During its Wuhan visit, the international team documented that there were already over a dozen strains of the SARS-CoV2 virus circulating in Wuhan in December – some linked to local animal markets and some now. And that is further testimony to its wider spread – Ben Embarek also acknolwedged in the CNN interview. And the team also had a chance to speak to the first patient Chinese officials said had been infected, an office worker in his 40s, with no travel history of note, whose infection was reported on December 8. During the meetings with WHO and international colleagues, Chinese scientists reported that there had been only 174 COVID-19 cases reported throughout Wuhan in December 2019. However, Ben Embarek stressed this was likely to be only the tip of the iceberg – since so many COVID-19 cases are mild or asymptomatic and thus go unreported. “We haven’t done any modeling of that since,” he said. “But we know …in big ballpark figures… out of the infected population, about 15% end up as severe cases, and the vast majority are mild cases.” Official Chinese Statements Peddle Frozen Food Theory The joint WHO-Chinese experts present the frozen food theory for the emergence of SARS-CoV2 in Wuhan a the 9 February press conference wrapping up the WHO -International expert mission. For the past several months, official Chinese statements have sought to shift the narrative around the virus origins elsewhere – suggesting at different times that it emerged from an infection at a military base, or from an animal source in South East Asia. But the favorite theory to be peddled has been that the virus arrived in Wuhan on frozen food packaging from imported products. “All available evidence suggests that (the coronavirus) did not start in central China’s Wuhan, but may come into China through imported frozen food products and their packaging,” stated The People’s Daily in an article in December 2020, At the joint WHO-China press conference earlier this month, Dr Liang Wannian, head of the Chinese expert panel on COVID-19, echoed that narrative once again, asserting that: “studies have shown that the virus can survive for a long time not only at low temperatures, but also at refrigerator temperature, indicating that it can be carried long distances on culturing products.” . Image Credits: @PeterDaszak, WHO. Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Sending Experts & Vaccines to Combat Widening Circle Of Ebola Virus In DR Congo & Guinea – Epicenter Of The 2014-2016 West Africa Epidemic 18/02/2021 Paul Adepoju & Raisa Santos New Ebola vaccines hold promise to curb various virus strains (Credit: WHO) The World Health Organization is set to deploy over 100 experts to Guinea – to respond to a widening circle of Ebola virus cases in a country that was also at the epicenter of the historic 2013-2016 West African Ebola outbreak, officials said at twin press events in Brazzaville and Geneva on Thursday. As critical new vaccines are being rushed to the region, there is a growing concern about transmission abroad, said Health Emergencies Executive Director Mike Ryan at a WHO press conference in Geneva. He noted that Guinea’s initial cluster of cases has occurred in proximity to Nzérékoré, the country’s second-largest city, at the crossroads of routes to Liberia, Côte d’Ivoire, and elsewhere. “Remember that these governments are currently responding to COVID-19 outbreaks in their own countries, while having to either respond to Ebola, or prepare for the potential arrival of Ebola,” said Ryan. WHO African Region Sounding Alarm Speaking at another press briefing in Brazzaville, WHO’s African Regional Director sounded an even greater note of alarm. “It’s a huge concern to see the resurgence of Ebola in Guinea, a country which has already suffered so much from the disease,” said Dr Matshidiso Moeti, WHO Regional Director for Africa at the briefing. However, banking on the expertise and experience built during the previous outbreak, health teams in Guinea are on the move to quickly trace the path of the virus and curb further infections,” she added, saying that “WHO is supporting the authorities to set up testing, contact-tracing and treatment structures and to bring the overall response to full speed.” WHO staff are already on the ground at Guinea, providing surveillance as well as ramping up infection, prevention, and control of health facilities. A humanitarian flight arrived on 15 February in N’Zerekore with 700 kg of medical equipment donated by WHO and partners. The country is also grappling with a surge of COVID-19 cases. On Feb 14 when the new Ebola outbreak in Guinea was announced, the country had also reported 72 new cases of COVID-19. As of Thursdsay, the cumulative number of confirmed COVID-19 cases in Guinea had risen to 15,088 with a total of 85 deaths. Using the glass half full or empty analogy, Moeti noted that Guinean response to COVID-19 and Ebola at the same time could be mutually reinforcing – building on already established guidelines and good practices, particularly around coordination, engaging with communities and leadership. “That also comes from preventive measures like physical distancing for COVID-19 and ‘don’t touch’ messages for Ebola, as well as the importance of hand hygiene for both,” she said. Rapid Ebola Vaccines Rollout – The Keys To Fast Containment House in Equateur Province gets disinfected following discovery of confirmed Ebola case there in August, 2020. Along with the outbreak in Guinea, another new DRC cluster has now emerged in Butembo. But like with COVID-19, vaccination will provide an even more durable response. A consignment of more than 11,000 doses of Ebola vaccine was expected to arrive in Guinea this weekend. In addition, more than 8,500 doses are being shipped from the United States for a total of 20,000 doses. Vaccination is set to kick off soon after they arrive. Some 4,000 kilometers away, another Ebola accination drive was just launched in the city of Butembo, Democratic Republic of Congo, on 15 February – shortly after another Ebola virus outbreak was detected in there on 7 February involving four cases and two deaths so far, according to WHO’s African Regional Office. But unlike Guinea, DR Congo did not have to wait for Ebola vaccines from Geneva or the US as it had 8,000 doses remaining from an Ebola outbreak last year, and thus was immediately able to commence immunizations. “So far nearly 70 people have been vaccinated against Ebola. The quick roll-out of vaccines is a testament to the enormous local capacity built in the previous outbreaks by the government, WHO and partners,” Moeti said. As a new and powerful Ebola control tool in both the Guinea and DR Congo response, WHO is simultaneously trying to step up procurement and rollout of a recently-approved Ebola vaccine through a new global vaccine stockpile. The vaccine was instrumental in finally stamping out a much larger 2018-2019 Ebola outbreak in the eastern part of the Democratic Republic of Congo. The single-dose Ebola vaccine (rVSV∆G-ZEBOV-GP, live), manufactured by Merck, Sharp & Dohme (MSD), received emergency regulatory approval from the US Food and Drug Administration in 2019. In addition, Johnson & Johnson also received European Medicines Agency approval last year for its Ebola vaccine, a two-dose regimen of Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo). “The ultimate endpoint for this is a multi-valent vaccine capable of protecting against multiple Ebola strains,” said Ryan at the briefing. The precise Ebola virus strain responsible for the Guinea outbreak has not yet been determined. The WHO, UNICEF, International Federation of Red Cross and Red Crescent Societies (IFRC) and Médecins Sans Frontières (MSF) announced in January the establishment of a global Ebola vaccine stockpile to ensure rapid response to future outbreaks. In his remarks in Geneva, Ryan lauded both Merck and Johnson & Johnson for pushing ahead with the R&D on the vaccines – as well as seeing to their production at cost. “These measures have been implemented to protect vulnerable populations,” said Ryan, adding that people at risk include “not just healthcare workers, but “occupational workers, charcoal workers, and people who work in the rainforest” – groups that might also have contact with animals carrying the Ebola virus. “This is really the holy grail of Ebola is to have those countermeasures in place, and not just be responding to outbreaks, but preventing the recurrence by the pre-emptive practical use of vaccination, which is always the best way to use vaccines.” Rapid Response in Guinea – Result of Hard Experience in 2013-16 West African Outbreak WHO has released some US$ 1.25 million to support the response in Guinea and to shore-up readiness in six neighbouring countries. “Within the epicentre of the outbreak in a border area, the sub-region is on high alert and authorities are reinforcing public health measures, including surveillance, to quickly respond to possible cross-border infections,” Moeti said. In other aspects of the response, Guinea’s Ministry of Health has activated national district and emergency management committees, and have advised the public to take measures to avert the spread of the disease, and to report any persons with symptoms to seek care. The ongoing, rapid response in Guinea and preparedness in neighboring countries is a result of the experience gained during the 2013-2016 outbreak in West Africa. The Ministry of Health of Guinea first reported to WHO about a cluster of Ebola Virus Disease (EVD) cases on 14 February, in the sub-prefecture of Gouécké, Nzérékoré Region, Guinea. Patient Zero was a nurse who originally presented at a health center in the region on 18 January 2021 with symptoms of headache, physical weakness, nausea, vomiting, loss of appetite, abdominal pain, and fever. She was diagnosed with malaria. On 24 January, she consulted with a traditional practitioner in Nzérékoré, and died four days later on 28 January. She was buried unsafely on 1 February in Gouécké, a town in the Nzérékoré Prefecture of Guinea. The other six known cases are her five family members and a traditional practitioner that she first visited for treatment. Of these seven reported cases, five people have already died. The other two confirmed cases are currently in isolation in dedicated health facilities in the Conakry and Gouécké, Nzérékoré region. As of 15 February, some 192 contacts of the nurse had been identified, including in N’Zérékoré Health District and 28 in Ratoma Health District, Conakry. To date, none of these contacts have reported traveling to neighboring countries. The Ebola virus strain responsible for the Guinea outbreak has not yet been determined. Image Credits: Trocaire/Flickr, Twitter: @WHO, WHO. WHO Official Walks Back On China Comments About Imported Frozen Foods As Possible Source Of 2019 Wuhan SARS-CoV2 Outbreak 18/02/2021 Elaine Ruth Fletcher Chinese and WHO-International team present findings Tuesday in Wuhan on joint study of the SARS-CoV2 virus origins in Wuhan briefing, 9 February. Since then, the narratives have diverged significantly. The WHO head of the international expert mission to China to investigate the origins of the SARS-CoV2 virus, told a press briefing Thursday that the international expert group is not seriously considering the Chinese theory that the virus outbreak in Wuhan, first infected Wuhan residents through imported frozen foods. The theory that imported frozen foods first brought the virus to Wuhan from another country -was promoted by the head of the Chinese expert team, Dr Liang Wannian, appearing on the stage with WHO team coordinator, Dr Peter Ben Embarek, at a joint press conference at the close of the joint WHO-China mission on 9 February – and undisputed by the WHO official at the time. That theory has since been discounted by other international experts that participated in the mission as both unlikely – and part of a broader propaganda package that Beijing is trying to sell abroad – to deflect international blame for the pandemic. Speaking about the discrepancies in the Chinese, WHO and international team statements for the first time, Ben Embarek discounted the possibility that the Wuhan virus outbreak had been sparked by contaminated frozen foods imported from abroad – calling such transmission a “very, very rare event” that could only occur after the SARS-CoV-2 virus was really widespread. However, Ben Embarek, a WHO food safety expert, did say that the investigative team is keen to get more data from China about whether wild animals that are farmed domestically in China – and sold on the Wuhan markets in both fresh and frozen forms – could have been the original source of the first animal-to-human virus leap, which then spread more widely among Wuhan residents in late 2019. Paving Over Differences In Chinese and WHO/International Narrative Dr Peter Benembarek, WHO head of the SARS-CoV2 investigative team mission to Wuhan, China In his comments at the Thursday briefing, Ben Embarek tried to paper over the obvious differences in the Chinese and international narratives. “We are talking about two very different situations,” Ben Embarek said at the briefing. “The first one is the possibility of reintroduction of the virus, through the frozen food chain, and through imported products back into China, where the virus has been more or less eliminated,…and where we know that there are multiple outbreaks in food factories in countries where the virus is circulated. “So that’s one line of interest, particularly for China and other countries in a similar situation. It’s a very very rare event, even China, through their extensives search for positive contaminated products have found only a very few positive cases.” The question of the first Wuhan cases in 2019, he added, “is a very different situation at that time, the virus was not widely circulating in the world. There were no large outbreaks in food factories around the world. And therefore, the hypothesis, the idea of importing the virus to China to that food is not something that we’re looking at there.” Ben Embarek also stressed that WHO and International expert team members would still like to get further information about possible infection chains in the domestic wild food products that were arriving in the market. Cautious WHO Statements In Wuhan Contrast With Bolster Media Remarks in Geneva – About Virus Origins and Earlier Spread Ben Embarek’s remarks about the team’s findings since leaving China have signalled a striking change in tone and pitch by the WHO leadership about the investigation. At the Wuhan press conference Embarek also said that the international investigators had not found any concrete evidence that the SARS-CoV-2 virus was circulating in Wuhan prior to December 2019 – another part of the Chinese official narrative. However in an interview Tuesday, Ben Embarek told CNN that the WHO-international team of investigators believed that the December 2019 outbreak in Wuhan, was much wider than previously thought – suggesting it also began earlier as well. . “The virus was circulating widely in Wuhan in December, which is a new finding,” he said. Other international team members have since complained bitterly that politics took precedence over science on key aspects of the mission,- and that Chinese authorities won’t turn over critical patient data that would allow the team to ascertain the breadth of the virus circulation in December 2019, as well as earlier. Ben Embarek has since admitted that the WHO-international team is also still seeking Chinese government permission to access to some 200,000 samples from Wuhan’s blood donor bank, which – if tested for virus antigens – could shed far greater light on the true prevalence of the virus in that period. “There is about 200,000 samples available there that are now secured and could be used for a new set of studies,” Ben Embarek told CNN. “It would be fantastic if we could [work] with that.” Chinese authorities have, however resisted sharing that data, claiming that they are only to be used for litigation purposes. “There is no mechanism to allow for routine studies with that kind of sample.” Over a Dozen SARS-CoV2 Virus Strains In Circulation in Wuhan In December, 2019 During its Wuhan visit, the international team documented that there were already over a dozen strains of the SARS-CoV2 virus circulating in Wuhan in December – some linked to local animal markets and some now. And that is further testimony to its wider spread – Ben Embarek also acknolwedged in the CNN interview. And the team also had a chance to speak to the first patient Chinese officials said had been infected, an office worker in his 40s, with no travel history of note, whose infection was reported on December 8. During the meetings with WHO and international colleagues, Chinese scientists reported that there had been only 174 COVID-19 cases reported throughout Wuhan in December 2019. However, Ben Embarek stressed this was likely to be only the tip of the iceberg – since so many COVID-19 cases are mild or asymptomatic and thus go unreported. “We haven’t done any modeling of that since,” he said. “But we know …in big ballpark figures… out of the infected population, about 15% end up as severe cases, and the vast majority are mild cases.” Official Chinese Statements Peddle Frozen Food Theory The joint WHO-Chinese experts present the frozen food theory for the emergence of SARS-CoV2 in Wuhan a the 9 February press conference wrapping up the WHO -International expert mission. For the past several months, official Chinese statements have sought to shift the narrative around the virus origins elsewhere – suggesting at different times that it emerged from an infection at a military base, or from an animal source in South East Asia. But the favorite theory to be peddled has been that the virus arrived in Wuhan on frozen food packaging from imported products. “All available evidence suggests that (the coronavirus) did not start in central China’s Wuhan, but may come into China through imported frozen food products and their packaging,” stated The People’s Daily in an article in December 2020, At the joint WHO-China press conference earlier this month, Dr Liang Wannian, head of the Chinese expert panel on COVID-19, echoed that narrative once again, asserting that: “studies have shown that the virus can survive for a long time not only at low temperatures, but also at refrigerator temperature, indicating that it can be carried long distances on culturing products.” . Image Credits: @PeterDaszak, WHO. Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Official Walks Back On China Comments About Imported Frozen Foods As Possible Source Of 2019 Wuhan SARS-CoV2 Outbreak 18/02/2021 Elaine Ruth Fletcher Chinese and WHO-International team present findings Tuesday in Wuhan on joint study of the SARS-CoV2 virus origins in Wuhan briefing, 9 February. Since then, the narratives have diverged significantly. The WHO head of the international expert mission to China to investigate the origins of the SARS-CoV2 virus, told a press briefing Thursday that the international expert group is not seriously considering the Chinese theory that the virus outbreak in Wuhan, first infected Wuhan residents through imported frozen foods. The theory that imported frozen foods first brought the virus to Wuhan from another country -was promoted by the head of the Chinese expert team, Dr Liang Wannian, appearing on the stage with WHO team coordinator, Dr Peter Ben Embarek, at a joint press conference at the close of the joint WHO-China mission on 9 February – and undisputed by the WHO official at the time. That theory has since been discounted by other international experts that participated in the mission as both unlikely – and part of a broader propaganda package that Beijing is trying to sell abroad – to deflect international blame for the pandemic. Speaking about the discrepancies in the Chinese, WHO and international team statements for the first time, Ben Embarek discounted the possibility that the Wuhan virus outbreak had been sparked by contaminated frozen foods imported from abroad – calling such transmission a “very, very rare event” that could only occur after the SARS-CoV-2 virus was really widespread. However, Ben Embarek, a WHO food safety expert, did say that the investigative team is keen to get more data from China about whether wild animals that are farmed domestically in China – and sold on the Wuhan markets in both fresh and frozen forms – could have been the original source of the first animal-to-human virus leap, which then spread more widely among Wuhan residents in late 2019. Paving Over Differences In Chinese and WHO/International Narrative Dr Peter Benembarek, WHO head of the SARS-CoV2 investigative team mission to Wuhan, China In his comments at the Thursday briefing, Ben Embarek tried to paper over the obvious differences in the Chinese and international narratives. “We are talking about two very different situations,” Ben Embarek said at the briefing. “The first one is the possibility of reintroduction of the virus, through the frozen food chain, and through imported products back into China, where the virus has been more or less eliminated,…and where we know that there are multiple outbreaks in food factories in countries where the virus is circulated. “So that’s one line of interest, particularly for China and other countries in a similar situation. It’s a very very rare event, even China, through their extensives search for positive contaminated products have found only a very few positive cases.” The question of the first Wuhan cases in 2019, he added, “is a very different situation at that time, the virus was not widely circulating in the world. There were no large outbreaks in food factories around the world. And therefore, the hypothesis, the idea of importing the virus to China to that food is not something that we’re looking at there.” Ben Embarek also stressed that WHO and International expert team members would still like to get further information about possible infection chains in the domestic wild food products that were arriving in the market. Cautious WHO Statements In Wuhan Contrast With Bolster Media Remarks in Geneva – About Virus Origins and Earlier Spread Ben Embarek’s remarks about the team’s findings since leaving China have signalled a striking change in tone and pitch by the WHO leadership about the investigation. At the Wuhan press conference Embarek also said that the international investigators had not found any concrete evidence that the SARS-CoV-2 virus was circulating in Wuhan prior to December 2019 – another part of the Chinese official narrative. However in an interview Tuesday, Ben Embarek told CNN that the WHO-international team of investigators believed that the December 2019 outbreak in Wuhan, was much wider than previously thought – suggesting it also began earlier as well. . “The virus was circulating widely in Wuhan in December, which is a new finding,” he said. Other international team members have since complained bitterly that politics took precedence over science on key aspects of the mission,- and that Chinese authorities won’t turn over critical patient data that would allow the team to ascertain the breadth of the virus circulation in December 2019, as well as earlier. Ben Embarek has since admitted that the WHO-international team is also still seeking Chinese government permission to access to some 200,000 samples from Wuhan’s blood donor bank, which – if tested for virus antigens – could shed far greater light on the true prevalence of the virus in that period. “There is about 200,000 samples available there that are now secured and could be used for a new set of studies,” Ben Embarek told CNN. “It would be fantastic if we could [work] with that.” Chinese authorities have, however resisted sharing that data, claiming that they are only to be used for litigation purposes. “There is no mechanism to allow for routine studies with that kind of sample.” Over a Dozen SARS-CoV2 Virus Strains In Circulation in Wuhan In December, 2019 During its Wuhan visit, the international team documented that there were already over a dozen strains of the SARS-CoV2 virus circulating in Wuhan in December – some linked to local animal markets and some now. And that is further testimony to its wider spread – Ben Embarek also acknolwedged in the CNN interview. And the team also had a chance to speak to the first patient Chinese officials said had been infected, an office worker in his 40s, with no travel history of note, whose infection was reported on December 8. During the meetings with WHO and international colleagues, Chinese scientists reported that there had been only 174 COVID-19 cases reported throughout Wuhan in December 2019. However, Ben Embarek stressed this was likely to be only the tip of the iceberg – since so many COVID-19 cases are mild or asymptomatic and thus go unreported. “We haven’t done any modeling of that since,” he said. “But we know …in big ballpark figures… out of the infected population, about 15% end up as severe cases, and the vast majority are mild cases.” Official Chinese Statements Peddle Frozen Food Theory The joint WHO-Chinese experts present the frozen food theory for the emergence of SARS-CoV2 in Wuhan a the 9 February press conference wrapping up the WHO -International expert mission. For the past several months, official Chinese statements have sought to shift the narrative around the virus origins elsewhere – suggesting at different times that it emerged from an infection at a military base, or from an animal source in South East Asia. But the favorite theory to be peddled has been that the virus arrived in Wuhan on frozen food packaging from imported products. “All available evidence suggests that (the coronavirus) did not start in central China’s Wuhan, but may come into China through imported frozen food products and their packaging,” stated The People’s Daily in an article in December 2020, At the joint WHO-China press conference earlier this month, Dr Liang Wannian, head of the Chinese expert panel on COVID-19, echoed that narrative once again, asserting that: “studies have shown that the virus can survive for a long time not only at low temperatures, but also at refrigerator temperature, indicating that it can be carried long distances on culturing products.” . Image Credits: @PeterDaszak, WHO. Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Crime And (No) Punishment: Why Africa’s Ports Are Vulnerable To Counterfeit COVID Vaccines 18/02/2021 Darren Taylor/Bhekisisa MOMBASA, KENYA – Africa’s ports are vulnerable to crime and corruption. Now they’re set to be the main thoroughfare for COVID vaccines entering the continent. Here’s why we need a better strategy to curb potential counterfeits coming through. Black-green tears of moss streak the facades of once-white buildings. The city is a maze of narrow streets, some cobbled with sea-stones, calcified by the centuries that have passed since they were laid. The air, always humid, is aromatic with sweet spices and fish, salt-washed from the nearby sea; the cacophony of the many markets and the muezzins’ call to prayer add to an atmosphere already heavy on the senses. There is rhythm here, in the cauldron of the Old Town, but it is offbeat – chaotic even. Mombasa, Kenya This is Mombasa — Africa’s fifth-busiest harbour, according to a report by financial advisory firm Okan and the Africa CEO Forum. Kenya’s chief port, it handles cargo for the whole of East Africa and parts of Central Africa. Because of its strategic position, Mombasa has been a place of conflict since at least the 1300s: Arabs, Persians, Portuguese and Turks have all fought wars over it. It’s also long been a haven for assorted miscreants. In the 1960s it was a favourite haunt of infamous soldier of fortune “Mad” Mike Hoare and his “Wild Geese” mercenaries. More recently, Mombasa sheltered one of the world’s most wanted terrorism suspects, Samantha Lewthwaite. The “White Widow” and alleged Al-Shabaab member, is wanted on charges related to several terror attacks in East Africa and has been implicated in the deaths of hundreds of people. The city today retains its reputation as an integral part of Africa’s criminal underbelly, being a major entry point for narcotics from the Middle East and illicit pharmaceuticals from Asia. Over the past 12 months, there’s been increasing talk in East African intelligence and law enforcement circles about the role Mombasa could play in facilitating shipments of falsified and substandard COVID-19 vaccines. Mombasa’ many organised crime groups have never been shy to miss out on new opportunities – and there are a lot of them. A September report by EU-funded anti-crime initiative, Enact, says Kenyan law enforcement puts the number of organised crime groups operating there at 132. Most are involved in trafficking cocaine and heroin from Asia and Latin America. Now, the port is set to become the primary conduit for vaccine supplies from India and China to landlocked East African countries such as Uganda, Rwanda and Burundi, plus South Sudan, Somalia and the Democratic Republic of Congo. More Goods Mean Fewer Inspections — Making It Easier for Criminals to Operate Interpol East Africa crime intelligence analyst John-Patrick Broome identifies Mombasa as a “key facility” for trade in falsified and substandard medicines. Already, he says, there’s been a noticeable reduction in inspections at Mombasa port and other ports in the region. It’s an unavoidable by-product of the pandemic: the port needs to receive medication and support from around the world if the region is to cope with COVID-19. “Inspection regimes have been reduced in order to facilitate the swift and hassle-free movement of items through the border, to be distributed across the region,” says Broome. This, however, also allows organised crime groups “to facilitate the movement of illicit medications” – most of them from Asia. An inspector at the port who spoke to Bhekisisa on condition of anonymity says as much. “At the moment we are only inspecting a small fraction of goods that come in. This is because our systems are overloaded with products. There’s so much cargo coming in that we have introduced trains that can transport double-stacked containers.” Containers at a port in Mombasa In the next few months, large consignments of vaccines will begin flowing into Africa, including jabs bought through international procurement mechanism COVAX. With cargo planes unlikely to handle the required volumes, they’ll be shipped to some of the continent’s many free-trade zones (FTZs), including Mombasa. It is at these FTZs that the vaccine supply chain will be most at risk of criminals inserting fake and substandard jabs, according to crime analysts, international anti-crime agencies and law enforcement officers. What is a Free Trade Zone? US think-tank Global Financial Integrity (GFI), which analyses financial crime around the world, has called FTZs “a Pandora’s box for illicit money” and a “haven for free crime”. It defines FTZs, otherwise known as free ports, as “special economic areas that benefit from tax and duties exemptions. While located geographically within a country, they essentially exist outside its borders for tax purposes.” By 2019, Africa was home to 189 of these FTZs, in 47 of 54 countries, according to the Africa Free Zones Association. Ten of them are in SA. And while FTZs are often found at ports, they can also be strategic inland hubs, as is the Musina-Makhado special economic zone in Limpopo, near South Africa’s border with Zimbabwe. Developing countries especially encourage the existence of FTZs, as they offer attract export businesses and foreign investment, and create jobs. But the GFI report warns: “Criminals see them as perfect places to manufacture and transport illicit goods, as controls and checks by authorities are often irregular or absent. Customs authorities have little or no oversight of what actually goes on in an FTZ, goods are rarely ever inspected and companies operating in FTZs tend to benefit from low disclosure and transparency requirements.” Criminals are Exploiting the Socio-Economic Impact of COVID by Offering Border Officials Bribes In the midst of the pandemic, the AU launched the African Continental Free Trade Area (AfCFTA) on January 1. With 54 signatories, it’s the largest trade bloc by number of members. According to the African Centre for Economic Transformation, the AfCFTA could create an economic bloc with a combined GDP of $3.4-trillion and grow intra-African trade by 33%. It’s not just a free-trade agreement. “It’s a vehicle for Africa’s economic transformation,” the centre notes. “Through its various protocols, it would facilitate the movement of persons and labour, competition, investment and intellectual property.” But a former trafficker in illicit medicines, who now co-operates with law enforcement investigating the crime in West Africa, warns: “I’m sure the AU means well by making Africa one big party of a free trade area, but that could not be more perfect for the gangs who are already bringing fake medicine into Africa … It’s like a ‘welcome to Africa’ sign is being held up for them.” Not that there weren’t risks prior to the launch of the AfCFTA. As intellectual property lawyers Marius Schneider and Nora Ho Tu Nam argue, Africa’s plethora of FTZs already unite organised crime groups specialising in the trade in illicit medicines. Schneider and Ho Tu Nam, advisers to some of the world’s largest pharmaceutical companies, authored a report in May that warned of the probability of falsified COVID-19 vaccines being distributed on the continent. “At ports like Mombasa, and other FTZs, pharmaceutical products are packaged and repacked in ways that disguise their origins,” explains Schneider. “There’s no doubt that the use of FTZs is facilitating and boosting trade in counterfeit pharmaceuticals … Could they have a role to play in crime around COVID vaccines? Definitely. Because in our experience they aren’t policed properly and they are also very open to corruption.” Broome says organised crime groups have been attempting to “corrupt” officials at East African ports to receive fake personal protection equipment consignments since the pandemic began. “The unfortunate context of COVID-19 in terms of its socioeconomic impact has led to a situation where individuals fear for their job security. And we’ve seen organised crime groups approach individuals with offers of payment in order to gain access to the reduced inspection capabilities that are present in the ports at the moment.” Djibouti – The end of the Silk Road … and the Possible Beginning of a Dark Journey with Fake Vaccines Schneider says Djibouti, which serves as Ethiopia’s port, is also a possible concern. “It’s at the end of the Chinese Silk Road; a major entry point of Chinese products into Africa,” he explains. “Djibouti is therefore in a very strategic position. It’s on one of the world’s busiest maritime commerce routes and links Asia, Africa and the Middle East.” In 2018, the small Horn of Africa state opened what will eventually be Africa’s largest single FTZ. Its various stages of development, funded by China, have cost about $US 3.5 billion. Several crime intelligence sources in East Africa are anxious about Djibouti, saying it’s ideal for organised crime groups to exploit when it comes to vaccine shipments because it doesn’t have a formal customs recorder (an electronic record of brands/trademarks and products that enter a country). “The Djibouti authorities don’t record brands; that means they don’t take any action in terms of alerting a company when there’s a suspicious shipment,” says a crime intelligence source, who asked not to be named. “The criminals are, of course, well aware of entry points like this, which have weaknesses that they can take advantage of.” Djibouti, Ethiopia Bhekisisa’s attempts to speak with Djibouti customs authorities were not successful, but Schneider confirms that it’s not their policy to notify companies in the event of suspected counterfeit goods. He says he recently made inquiries of the Djibouuti authorities. “There is a possibility of signing a kind of memorandum of understanding with their customs [service] and then they may look after your products,” he explains. “But it’s not something that’s provided for and that’s de facto done; in countries such as SA and Mauritius, on the other hand, co-operation with customs to seize illicit goods works quite well.” North & West Africa Entry Points – Libya, Lomé and Cotonou Last July, a research brief by the UN Office on Drugs & Crime (UNODC) also identified the ports of Lomé (Togo) and Cotonou (Benin) as key entry points for falsified and substandard pharmaceutical products related to the COVID-19 pandemic. According to Mark Micallef of the Global Initiative against Transnational Organised Crime, Libya is currently the “epicentre” of trafficking in falsified, substandard and stolen pharmaceuticals in North Africa and the Sahel region. “Drug trafficking in general grew exponentially in Libya after 2011 [when the regime of Muammar Gaddafi was overthrown], with new players, new markets developing and prescription medication and counterfeit pharmaceuticals being a very big growth market, and rapid growth also of an internal market which, prior to the revolution, was pretty much controlled very strictly by the regime.” Micallef says there are “key nodes in ports and strategic border areas that are completely operational for criminal business” and that could easily function as conduits for falsified COVID-19 vaccines. Servicing Landlocked Countries puts South Africa’s Points of Entry under Immense Pressure Like other customs officials Bhekisisa spoke with in several African regions, a Mombasa inspection officer says he’s “under a strict order” to “concentrate on shipments coming in from Asia” when trying to detect possible falsified vaccines. But the instruction has left him frustrated and disenchanted. “These days everything comes from China,” he says. “We don’t have the capacity to inspect everything that is entering from Asia; no way! We can only look at a few, so lots of illegal stuff is getting past us here, but there is nothing we can do about it.” Ho Tu Nam says if there are “bottlenecks” of vaccines at Africa’s points of entry, organised crime groups will try to exploit the chaos. “About a third of Africa is landlocked, so you have a few ports [like Mombasa and Durban] serving many countries,” she points out. Six landlocked countries will depend on South Africa’s points of entry to process and distribute large consignments of vaccines, especially from China and India. These include: Botswana, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe. On South Africa’s eastern coast, the KwaZulu-Natal’s provincial Department of Transport describes Durban as the largest and busiest shipping terminal in sub-Saharan Africa and the fourth-largest container terminal in the southern hemisphere – one that links “the Far East, Middle East, Australasia, South America, North America and Europe. It also serves as a trans-shipment hub for East Africa and Indian Ocean islands.” Durban, Kwa-Zulu Natal Province, South Africa Ho Tu Nam says organised crime groups could take advantage of busy points of entry by mislabelling consignments of falsified and substandard medicines as “in-transit” goods. “We’ve noticed a lot of counterfeiters are labelling their products, going for example through the port of Mombasa, as destined for South Sudan, destined for Rwanda. The customs officers are so busy, and so focused on products marked for distribution in their own country, that they don’t check those labelled ‘in-transit’. Once those mislabelled products hit the road, they’re diverted into local markets.” The “Little Chemist” Threat In East Africa, several police officers tell Bhekisisa they’re concerned that falsified, substandard and stolen COVID vaccines could be distributed by some of the region’s many thousand informal “chemists”. It’s a valid concern, says Interpol. “The number of unlicensed pharmacies has increased across the region during COVID-19,” says Broome. “We see an example of this during this period where 56 arrests were made in Uganda and there was the closure of 1,526 facilities. These enable, for example, the sales of fake antivirals imported from Asia.” Broom says members of organised crime groups are trying to “franchise” some illegal pharmacies all over East Africa, “which would give them an even greater air of legitimacy”. But according to Micallef, it’s the legal and as well as the illegal pharmacies that are important channels for the flow of illicit medicines throughout North Africa, and specifically the Maghreb countries of Algeria, Libya, Mauritania, Morocco and Tunisia. Across the continent, one-person, one-family operations, often doing business from informal settlements or mobile units such as the back of pickup trucks, offer an important source of cheaper genuine medicine to populations that could otherwise not afford treatment. Law enforcement agencies say criminals frequently use such pharmacies as “fronts” and “channels” for illicit pharmaceuticals. Crime analyst Maurice Ogbonnaya, a former security official in Nigeria’s National Assembly, explains: “They’re notoriously difficult to control, because they’re mobile; and if the police start inspecting them they just shut for a while before opening again, or they relocate.” Lack of Punishment Means Criminals aren’t Afraid to Produce Fake Medicines There’s been progress in developing frameworks around substandard and falsified medical products over the past decade, says the UNODC. But “few countries have an adequate legal and regulatory system in place to address substandard and falsified medical product-related crimes associated with COVID-19”. And, says Schneider, if the past is anything to go by, punishment for people in Africa caught distributing falsified vaccines won’t be harsh. “Fake medicine is usually regarded as a violation of intellectual property rights and not a crime in many parts of the world, including Africa,” he explains. Cyntia Genolet, associate director of Africa engagement at the International Federation of Pharmaceutical Manufacturers and Associations, says that’s precisely why organised crime groups could be inspired to invest in falsified and substandard inoculations. “If you don’t have any [real] punishment, you just take the risk, then maybe you have three days of jail, you pay your small fine, and then you’re good to continue,” she says. In 2018, an OECD report identified Egypt as a continental hub for trade in, and production of, illicit products. However, in that year, the country made just one arrest for the manufacturing of counterfeit medicines. Disturbingly, that single arrest was enough to put Egypt among the top 10 countries for the number of arrests for such a crime. “That says it all about how seriously not just Africa, but the world, has taken this issue so far,” says Schneider. “If you’re caught in the Comoros, for example, selling counterfeit pharmaceuticals, they will let you get away with a fine and you will be able to walk away with your fake products.” Bust with fake pharmaceuticals worth R95-million – but the criminals walked free Andy Gray, a senior pharmacist at the University of KwaZulu-Natal, recalls what is arguably SA’s most infamous case of trade in falsified medicines, for which the perpetrators also got off extremely lightly. In 2000, police raided a factory in Potchefstroom and confiscated pharmaceuticals, many smuggled from India, with a market value later estimated at 95-million Rand (about US$ 15 million). Two years later, a magistrate concluded that three pharmacists from the North West city – Derrick Adlam, Deon de Beer and Johan du Toit – had operated a syndicate that repackaged and distributed falsified, stolen and expired medicines. The three pled guilty – but only to contravening the trademarks act. Each received a suspended five-year jail term and was set free immediately after paying a fine. Poor Quality, Fake Vaccines will have a “Chilling Effect” Ogbonnaya says some government agencies, especially in West Africa, are trying to confront the trade in illegal pharmaceuticals, but most action is taken by individual governments focusing only on local crimes. Organised crime groups, he points out, operate regionally, continentally and globally, so what’s needed is corresponding cross-border co-operation. “What you have in some African countries right now is every few months or even years you’ll have raids and arrests, and shutting down of illegal pharmacies, for example, and then a few months after that, the criminals are up and running again,” says Ogbonnaya. “This is a well-entrenched system and it’s not one that will end with a few arrests here and there. It will be prevented in a big way by co-ordination between law enforcement, governments, pharmaceutical manufacturers and many other actors. And that’s what’s missing at the moment, co-ordination. Africa, and the world, needs a single system focused on the illicit medicine trade, and we don’t have that.” In 2010 the Council of Europe drafted and adopted the Medicrime Convention – the only international legal instrument providing the means to criminalise the falsification of medical products as a public health threat. But only 18 countries have ratified it so far. Of those, three are African: Benin, Burkina Faso and Guinea. “So, they are the only three [countries] in Africa that actually make falsification of medicines a crime,” says Genolet – though it’s hoped that more will ratify the agreement soon. Ruona Meyer, the producer of Sweet, Sweet Codeine, an Emmy-nominated documentary on the illegal trafficking of medicine in Nigeria, says she’d like to see an example being made of the first person or group caught distributing falsified, substandard or stolen COVID-19 vaccines in Africa, no matter where that may happen. “It would be a big help if the law enforcement authorities stamp out the fires of fake vaccines as soon as the flames start,” she says. “Get these dealers into court and into jail as fast as possible to deter organised crime. The fake vaccine cases must be expedited and must be very, very public,” she says. [WATCH] Sweet Sweet Codeine: What Happened Next? But, Salim Abdool Karim, co-chair of South Africa’s scientific ministerial advisory committee on COVID-19, warns that falsification in itself could do “tremendous harm” to people’s faith in the safety of the jabs. Gray similarly believes any wave of falsified vaccines in SA could have a “really chilling effect on people’s confidence and trust, both in government and in the regulatory authority”. “We already have vaccine-hesitant parents and members of the public in this country. If we want to eventually vaccinate 70%of the population, we can’t have a third or half of them refusing that vaccination. And anything which breaks down trust – be it mismanagement of adverse effects after genuine vaccination, or experience of a falsified vaccine or suddenly it’s arriving in strange places and people are being [vaccinated] on the pavements – that’ll hit the press very quickly and I think it could be really damaging.” This article is the second in a series, produced by the Bhekisisa Centre for Health Journalism. The first story, LIttle Vials, Big Crime: Criminals Primed For Onslaught On Africa’s Vaccines was pubilshed on 11 February 2021. The work is supported by a grant from the Global Initiative Against Transnational Organised Crime (GI-TOC). Sign up to Bhekisisa’s newsletter. Image Credits: Kyle Steckler, U.S. Navy/Flickr, Flickr, Bhekisisa, Sinny Pak/Flickr, Michael Jansen/Flickr, Bhekisisa. Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Europe To Establish Emergency Biodefense Plan To Respond To Coronavirus Variants – More Local Manufacturing For Rapid Scale Up Of New Vaccines & Boosters 17/02/2021 Svĕt Lustig Vijay The European Comission has announced a new plan to respond to coronavirus variants The European Commission will establish an emergency biodefense plan to prevent, mitigate and respond to new variants of the coronavirus that are supercharging transmission and threatening the performance of available vaccines. Creation of a voluntary licensing mechanism involving local manufacturers is one of the strategies proposed in the plan to hasten the production of updated vaccines. “This very real threat of variants requires determined, collective and immediate action,” said the European Commission on Wednesday. “The Commission will establish and operate a new bio-defence preparedness plan called HERA Incubator, to access and mobilise all means and resources necessary to prevent, mitigate and respond to the potential impact of variants.” With at least €75 million ($90.2 million) in initial funding, the EU’s five-pronged plan aims to rapidly detect variants and to adapt vaccines accordingly, while ensuring their approval is fast-tracked and that production is upscaled. “The Commission will foster the creation, if need be, of a voluntary dedicated licensing mechanism, which would allow technology owners to retain a continued control over their rights whilst guaranteeing that technology, know-how and data are effectively shared with a wider group of manufacturers.” Specifically, the Commission aims to urgently work towards: Rapid detection of variants; Swift adaptation of vaccines; Setting up a European Clinical Trials Network; Fast-tracking regulatory approval of updated vaccines and new or repurposed manufacturing infrastructures; Enable upscaling of production of existing, adapted or novel COVID-19 vaccines. Until now, only one major European vaccine-developer, AstraZeneca, has licensed its vaccine voluntarily with a number of manufacturers around the world – thus sharing the vaccine know-how with producers in India, the Republic of Korea and Brazil, among other countries. The EC initiative comes on the heels of a call by the new Director General of the World Trade Organization, Ngozi Okonjo-Iweala, to encourage vaccine pharma companies to issue more voluntary licenses to manufacturers in low- and middle-income countries so as to open up the global bottleneck in access to vaccines. She also called upon countries to support the ramping up of such local production capacity in low- and middle-income countries, noting that on the African continent, for instance, 90% of medical products are imported, Iweala said shortly after her election by the WTO General Council on Monday. Medicines Access Advocates Say European Commission Plan Is To Euro-Centric While seeming to echo Iweala’s approach, health advocacy groups voiced concerns that the EC initiative was too Eurocentric. Notably, the Commission’s plan did not explictly mention any push to expand voluntary licensing internationally – through efforts such as the WHO-backed initiative to created a COVID-19 Technology Access Pool (C-TAP) for the voluntarily licensing of COVID-19 vaccines and other COVID health products. Nor did the EC explicitly mention the WHO co-sponsored global vaccine facility COVAX – which is struggling to recruit more funds and vaccines to distribute to low- and middle-income countries “The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by [WHO Director General] DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global,” said Knowledge Ecology International’s Jamie Love in a tweet. The EU proposal today, and the comments by the incoming WTO DG Ngozi Okonjo-Iweala, as well as earlier comments on CTAP by @DrTedros seem at odds. EU proposal on licensing seems focuses on EU needs, not global. — James Packard Love (@jamie_love) February 17, 2021 In a followup remark to Health Policy Watch, Love added, “we have some details but there is a lot we don’t know yet [about the EC plan].” I am guessing that the EU sees any new capacity as serving the whole world, but it seems to focus on ramping up EU based manufactureing and addressing EU vaccine security needs, as its priority, very similar to what other governments, including the US, have done. “If the EU wants to work on a more global technology transfer initiative, it would want to engage in C-TAP, and maybe even help C-TAP get its programme off the ground in a meaningful way.” On the other hand, the EC plan stresses that the benefits of the European initiative will extend “far beyond” the EU’s borders through cooperation with low- and middle-income countries, particularly in Africa and global health bodies like the World Health Organization, GAVI, The Vaccine Alliance and the Coalition for Epidemic Preparedness Initiatives (CEPI). “In the medium and long-term, the EU should cooperate with lower and middleincome countries, in particular in Africa to help scale up local manufacturing and production capacities,” said the Commission’s plan. The European Commission plan also “emphasizes that the sharing of know-how will be restricted and controlled,” Love added. “Such conditionality diverges from the open-access vision of the WHO co-sponsored C-TAP, but that “may be what is feasible” for vaccines already being marketed now as products with patent restrictions. However, for new products, Love said the EU model would be more effective if it were based around “open sharing of the tech, and even some existing technology can be put into the public domain through tech buyouts. There is too much embracing the model of proprietary manufacturing know-how, when that is the opposite of what is needed for scaling up and making access more fair.” The European Union’s Vaccine Strategy has so far secured access to more than 2 billion doses of coronavirus vaccines, which is roughly double the amount needed to vaccine the EU’s 450 million citizens. And just this Wednesday, the European Commission sealed a deal with Moderna for 150 million additional doses of its vaccine, bringing its order to a total of 310 million doses for this year, and an option to purchase 150 million extra doses in 2022. Image Credits: almathias. United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
United Kingdom, Norway & UNICEF Reaffirm Calls for “Global Cease Fire” in UN Security Council Open Debate on COVID-19 Vaccines Access 17/02/2021 Elaine Ruth Fletcher MSF relief worker administers a pneumonia vaccine to a child in Greece as part of a 2016 campaign targeting refugees arriving in Europe – Photo: MSF/ Sophia Apostolia The United Kingdom, Norway and UNICEF on Wednesday appealed to world leaders to give stronger backing to UN Secretary General Antonio Guterres’ call in March 2020 for a “global cease-fire” in order to beat the COVID-19 pandemic and get vaccines to tens of millions of undocumented migrants and refugees, as well as people living in conflict zones. The latter includes some 60 million people living in areas controlled by non-stated armed groups, according to estimates by the International Committee of the Red Cross (ICRC). They spoke during an open debate on getting COVID-19 vaccines to conflict zones, underway in the UN Security Council on Wednesday. The debate brings together foreign ministers from nearly a dozen other countries, including the United Kingdom, United States, China, India, Kenya, Mexico, Tunisia and Ireland – to address barriers to ensuring that the vaccine rollout can reach the most vulnerable – including nbot only people living in conflict zones, but also migrants and unregistered immigrants. Conversely, the role of the pandemic in exacerbating ongoing local and regional conflicts is also on the agenda. UK Foreign Secretary Dominic Raab, who was chairing the virtual debate, on the implementation of UN Security Council Resolution 2532, on the cessation of hostilities in the context of the COVID-19 pandemic, which was adopted in July, 2020, noted that some 160 million people in countries such as Yemen could miss out on vaccines due to war. United Nations Security Council debate on vaccine access in conflict zones British Prime Minister Boris Johnson is expected to set out more details on vaccinating refugees and people in conflict zones at a virtual meeting of G7 leaders on Friday. “The COVID-19 pandemic has been a stress test of national and global health systems and our systems of governance,” said Norway’s Foreign Minister Ine Marie Eriksen Søreide. “Now we, as an international community, and as this Security Council, must forge a united way forward.” The Norwegian minister said that the Scandanavian country was advocating three key principles in terms of the pandemic battle: ensuring equitable global access to COVID-19 vaccines; humanitarian access for vaccines to reach the most vulnerable; and the global cease-fire. “Hostilities must cease in order to allow vaccination to take place in conflict areas,” said Søreide. “In many conflict areas, civilians and combatants are living in territories controlled or contested by non-state armed groups. Reaching these populations may involve engaging with actors whose behaviour we condemn. The successful dialogues with armed groups in Afghanistan, Syria and elsewhere to allow humanitarian access for polio and other health campaigns offer lessons for the rollout of COVID-19 vaccines.” She added: “From Idlib to Gaza, from Menaka to Tigray: It is our duty as the Security Council to keep a close eye on these shifting dynamics, to coordinate efforts, and to facilitate full and unimpeded humanitarian access, as well as peaceful resolution of conflicts. We must call for concerted action across all the pillars and institutions of the UN to secure the widest and most equitable distribution of COVID-19 vaccines.” Her remarks came shortly after Israel agreed to allow the transfer of some 2000 vaccines donated by Russia to the barricaded Gaza Strip, despite demands by some Israeli parliamentarians that Gaza’s Hamas rulers first return two Israelis being held hostage in the Strip, Avera Megistu and Hisham al-Sayed, as well as the bodies of two Israeli soldiers killed in border skirmishes. Norway supports a global #COVID19 ceasefire. FM Eriksen Søreide’s key message to #UNSC: ▶️ Ensure equitable global access to #COVID19 vaccines ▶️ Humanitarian access key for vaccines to reach the most vulnerable ▶️ Hostilities must cease to allow vaccination in conflict areas https://t.co/GR05mCwr6A pic.twitter.com/JSZxA6Xpsl — Norway MFA (@NorwayMFA) February 17, 2021 India Calls On Countries to ‘Stop Vaccine Nationalism & Hoarding’ – Offers 200,000 Sergum Institute Vaccine Doses To UN Peacekeepers as a Gift Indian External Affairs Minister S Jaishankar Meanwhile, India’s External Affairs Minister S Jaishankar announced that India will provide 200,000 doses of COVID-19 vaccines to UN Peacekeepers – India’s vaccines are being locally produced by the Serum Institute of India under a license from AstraZeneca. “Keeping in mind UN Peacekeepers, we would like to announce today a gift of 200,000 vaccine doses for them,” he said. Jaishankar protested what he described as the “glaring disparity” in vaccines access, calling for stronger member state “cooperation within the framework of COVAX, which is trying to secure adequate vaccine doses for the world’s poorest nations,” and outlined a nine-point plan to: “Stop ‘vaccine nationalism’; ….actively encourage internationalism” and combat pandemic and vaccine disinformation. He called out rich countries that have purchased multiple doses for every citizen stating that: “hoarding superfluous doses will defeat our efforts towards attaining collective health security.” Henrietta Fore – Countries Also Must Restart Vaccine Campaigns Against Other Diseases A refugee filling an application at the UNHCR registration center in Tripoli, Lebanon. Meanwhile, UNICEF’s Henrietta Fore said that her agency was working hard to support a plan to distribute some two billion vaccines in low- and middle-income areas over the course of 2021 through the COVAX global vaccine facility, co-sponsored by WHO, GAVI-The Vaccine Alliance, and CEPI, the Oslo-based Coalition for Epidemic Preparedness Initiative. However, UN member states must “include the millions of people living through, or fleeing, conflict and instability” in their national vaccine planning, “regardless of their legal status or if they live in areas controlled by non-state entities.” Fore described it “not only as a matter of justice. But as the only pathway to ending this pandemic for all.” Restarting stalled immunization campaigns for other diseases remains equally critical, she said, adding: “We cannot allow the fight against one deadly disease to cause us to lose ground in the fight against others.” UNICEF Lays Out Huge Logistics Challenges Of Vaccine Campaigns Physical distancing measures have been set up by the UN in a refugee camp in South Sudan, where rations have been increased to reduce the number of times large groups need to gather to receive humanitarian aid. In her remarks, Fore also laid out the huge logistics challenges that the agency is facing, together with its partners – as well as the challenge of reaching a vaccine target audience of older people that is not typically a UNICEF focus. “Using existing immunization infrastructure, we’re also working to reach people not normally targeted in our immunization programmes — including health workers, the elderly and other high-risk groups,” Fore said. “We’re helping governments establish pre-registration systems and prioritizing which people, such as health-care workers, need to receive vaccines first. “We’re engaging communities and building trust to defeat misinformation. “We’re training health workers to deliver the vaccine, and helping governments recruit and deploy more health workers where they’re needed most. “We’re advocating with local and national governments to use other proven health measures like masks and physical distancing. “And now, through the COVAX Facility, we’re working with Gavi, WHO and CEPI to procure and deliver the COVID vaccines in close collaboration with vaccine manufacturers, and freight, logistics and storage providers. The daunting challenges also mean ensuring that enough syringes are available for the available doses in each country, procuring syringes and safety boxes, and inventories of cold chain systems. “It means finding ways to ensure distribution and delivery in logistically difficult contexts like South Sudan or DRC — or high-threat environments like Yemen or Afghanistan,” she said. “It means negotiating access to populations across multiple lines of control by non-state armed groups — areas that the ICRC estimates represent some 60 million people.” Image Credits: UNHCR/Elizabeth Marie Stuart, MSF/ Sophia Apostolia, Mohamed Azakir / World Bank. U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
U.S. Will Pay WHO Over $200 Million By End of February 17/02/2021 Editorial team Secretary of State Antony J. Blinken The United States will pay over $200 million it owes to the WHO by the end of February, marking a positive step to restabilize the global health body’s fragile finances at a time when they are most needed. “This is a key step forward in fulfilling our financial obligations as a WHO member and it reflects our renewed commitment to ensuring the WHO has the support it needs to lead the global response to the pandemic,” said U.S. Secretary of State Antony Blinken at the U.N. Security Council on Wednesday. “The United States will work as a partner to address global challenges. This pandemic is one of those challenges and gives us an opportunity not only to get through the current crisis, but also to become more prepared and more resilient for the future.” The move comes less than a month after the Biden administration rejoined the WHO as part of its seven-point pandemic plan, reversing former president Donald J Trump’s plan to withdraw from the Organization and suspend its contributions. In 2019, the US was the global health body’s largest donor, with a US$400 million contribution that represented 15% of the WHO’s annual budget. In total, the Organization’s budget equates to that of two sub-regional hospitals. The US will also provide “significant” financial support to the international COVAX facility to equitably distribute vaccines around the world, added Blinken. Co-led by WHO and Gavi, the Vaccine Alliance, COVAX is still facing a US $27 billion shortfall in funding. Image Credits: U.S. Department of State / Ronny Przysucha. Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Reimagining Public Health 17/02/2021 Jose Luis Castro The pandemic has revealed that health must be woven into all aspects of society – from our workplaces to schools, businesses as well as the government. The COVID-19 pandemic has revealed the profound dangers of having social, economic and health care systems that marginalize public health. To go forward, we must start by looking back. We must build a stronger foundation with better systems that can prevent future pandemics and also weave health into all aspects of society, from our workplaces to our schools to our businesses to every action of government. We can work for a world where people have equitable access to health care, and where they are protected from the leading drivers of death and disease no matter their race, gender, or sex or where they live. Here are five critical priorities: Invest in Epidemic Preparedness We know that the next pandemic is only a plane flight away. Every level of government must do better to be prepared. We must seize and build on the public interest and political will that has been created by the experience of living through and witnessing the impact of COVID-19 This means investing in global surveillance systems like the WHO’s Joint External Evaluation (JEE) tool so that new outbreaks can be identified and contained. Spurred by the 2014 Ebola crisis, the JEE provides a way for countries to assess their ability to find, stop and prevent epidemics, and target improvements. We need to accelerate this process so that every country completes a JEE. We need to provide funding for improvements—an estimated investment of just US $1 per person per year could significantly blunt the health and economic costs of future epidemics. Consider the alternative—The International Monetary Fund estimates the impact of COVID-19 is at least US $28 trillion in lost output. And then, technical assessments and competency are not enough—the countries that did the best to address COVID-19 also had strong and coordinated leadership across agencies and levels of government, depended on science to guide their actions rather than political considerations, and carried out effective public communication. Invest in Prevention of Noncommunicable Diseases Governments need to prioritize prevention to slow the staggering increase in conditions like cancer, diabetes and high blood pressure—noncommunicable diseases that cause up to 80% of premature deaths throughout the world. Investing in prevention will save trillions in treatment. This means properly resourcing national and state ministries of health and urban health departments that are too often poorly funded. In the United States, a paltry 3% of all health spending goes to public health. Public health protections may seem invisible—a tax on sugary drinks to discourage consumption, strong surveillance data that improves resource allocation, the absence of tobacco advertising—but COVID-19 has brought new visibility and public and political support for greater investment in health. Public health entities are essential and must be properly funded. We have a rare opportunity to implement a comprehensive approach to health. Let’s not lose the moment. Build Economies Around Health There’s growing momentum behind the idea that successful economies prioritize investments in the wellness of people. We can better harness the power of economic policy and partnerships. Even before COVID-19, more than 100 CEOS of leading Fortune 500 companies came together to declare that company performance must be measured in more than shareholder returns. Among its ideals: investing in their employees and protecting the environment. Let’s empower large employers to invest in the health of employees—including mental health—and promote business practices that promote healthier environments including fewer health-harming emissions. Governments can tilt economies away from ill health by ending subsidies for products with negative impacts on health—tobacco, alcohol and fossil fuels—and taxing unhealthy commodities. This will reduce health care costs and generate revenue for social good. Policies can make healthy choices the easy choice for people, by making fruits and vegetables more affordable, junk food less accessible, informing consumers with clear warning labels on packaged food, and promoting smart city designs that create safer spaces for walking, biking and playing. Put Equity at the Center COVID-19 has laid bare the tragic scope of health inequities across many dimensions. In the United States, Black, Indigenous, and Latinx Americans are dying from COVID-19 at triple the rate of white Americans. As the vaccine rollout continues, it is critical that the shots are distributed to the Black, Indigenous, and Latinx Americans communities to avoid exacerbating existing health disparities. Globally, a Duke University study warns that billions of people in low- and middle-income countries will not have access to the COVID-19 vaccine until 2023, and in some cases, 2024. Until all people are protected equally, we must concentrate investments—not only for COVID-19 but also on the myriad health problems exacerbated by inequity—in communities that are disproportionately affected and work to address root causes. This means speaking out, partnering with all levels of government and other sectors such as education and housing where good health is rooted, and empowering the most-affected groups to shape the health and social policies that have placed disproportionate health burdens on them. Increase Global Cooperation The weakness of our global health coordination systems was one reason a preventable epidemic mushroomed into a global pandemic. Formal mechanisms of global cooperation from the Paris Climate Change Treaty to the Framework Convention on Tobacco Control, bring country accountability. Alternatively, we can strengthen health-related components of existing frameworks, such as demonstrating that the Conventions on the Rights of the Child includes committing to access to healthy nutrition and protecting children from the unhealthiest commodities. We must also bolster our coordination bodies and mechanisms across multilateral organizations and governments, focusing first on the World Health Organization. In revealing systemic weaknesses, COVID-19 also has painted a way forward for greater progress. Together, we can reimagine a world where everyone is protected by a strong public health system so they can lead longer, healthier lives, where science is the core of public health decisions and measures, and where we can effectively prepare for and even prevent future pandemics. This will not be our last. José Luis Castro, president and CEO of global health organization Vital Strategies Image Credits: Vital Strategies, Tewodros Emiru, Vital Strategies. Posts navigation Older postsNewer posts